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Abstract 
 
This thesis describes a novel computational method developed to identify 
and characterise points of protein-protein interaction between two G protein-
coupled receptors (GPCRs). An ensemble-based coarse-grained molecular 
dynamics (eCG-MD) approach was applied to GPCR oligomers with 
experimentally-determined contact interfaces (adenosine A2A receptor, 
rhodopsin, CXCR4 and β1AR). Error analysis was used to determine 1) the 
number of replicas in an ensemble and 2) the simulation time for each replica 
that were needed to obtain convergence with experimental results. Error analysis 
also enabled identification of non-interacting regions. 
 
This novel method yielded calculations of distance between rhodopsin, 
CXCR4 and β1AR transmembrane domains reported to form contact points in 
homodimers that correlated well with the corresponding measurements obtained 
from the structural data, demonstrating an ability to predict contact interfaces 
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computationally. The method gave distance measurements between residues 
shown to be involved in oligomerisation of the fifth transmembrane domain from 
the adenosine A2A receptor that were in very good agreement with the existing 
biophysical data. Further, the method provided information about the nature of 
the contact interface that could not be determined experimentally.  
 
This CG-MD method was then used as a high-throughput screen to 
identify novel sites of interaction in the adenosine A2A receptor, informing the 
design of future experimental work. Experimental methods to investigate 
interactions are also described in this thesis. These were less successful in 
identifying contact points, however, the present computational method will 
enable novel interaction points between GPCRs to be predicted and tested 
experimentally using assays of ligand binding and receptor signaling. 
 
In conclusion, this work provides an accurate, reproducible and reliable 
method for determining the specific points of interaction between GPCR dimers. 
The eCG-MD method discriminates between residues in TM helices that form 
specific interactions and residues that are in close proximity but do not interact. 
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Chapter 1 
Introduction 
 
1.1 G protein-coupled receptors 
G protein-coupled receptors (GPCRs) are a well-studied family of 
membrane proteins also known as seven transmembrane (7TM) receptors. They 
are the largest, most diverse group of cell surface receptors located in a wide 
variety of tissues, and organs. They respond to various numbers of chemical 
signals in a highly selective way and then transduce the signal from these 
interactions into numerous intracellular responses. Not only are they a large and 
important group of signaling proteins, they are also the targets for about 40% of 
all therapeutic compounds in clinical use. Although over 800 human proteins are 
classified as GPCRs, drugs have been developed against fewer than 10% of these 
targets[1, 2]. GPCRs are responsible for transducing signals from the most 
divergent repertoire of stimuli, including light, calcium ion, nucleotides, amino 
acids, biogenic amines, odorants, pheromones, sweet and bitter tastes, lipids, 
peptides, and glycoproteins. Thus there is huge potential to expand the number of 
targets for which new therapies can be designed. Novel therapeutic design is also 
important if one of the goals of personalized medicine, to develop new drugs for 
patient-specific variations of GPCRs, is to be achieved.  
 
There are five main classes of 7TM superfamily: class A (rhodopsin-
like), class B (secretin receptor family), class C (metabotropic 
   Chapter 1: Introduction 
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glutamate/pheromone), class E (cAMP receptors) and class F (frizzled and 
adhesion). The conservation of sequence identity across the huge 7TM family 
members is significantly low, however, sequence alignments of 7TM receptors 
reveal shared traits that form the basis for classification into families[3]. 
 
1.1.1  GPCR structure 
All GPCRs have a common core structure, which consists of a single 
peptide chain that spans the plasma membrane seven times (see Figure 1.1). 
Experimental visualization of this was shown with the publication of the first 
GPCR crystal structure in 2000, when bacteriophage rhodopsin and bovine 
rhodopsin were crystallized at 1.55 and 2.8Å respectively[4]. The second 
structure obtained was that of the β2-adrenergic receptor by Kobilka and 
coworkers in 2007[5, 6].  
 
The past 14 years, and in particular the last five years, have seen an 
explosion in the solving of GPCR crystal structures in multiple receptor states 
(for example, unliganded, in complex with agonist, in complex with antagonist, 
etc.). This breakthrough in the understanding of GPCR structure and function has 
enabled significant advances in the design of GPCR ligands using computational 
methods and has facilitated a better understanding of ligand-receptor 
interactions[2]. A list of the GPCR crystal structures published to date is given in 
Table 1.1.  
   Chapter 1: Introduction 
 18 
 
 
 
Figure 1.1 A schematic representation of GPCR structure  
The seven TM helices embedded in the lipid bilayer of the plasma membrane (in blue) are shown 
(in red) with arrows indicating directionality from the amino to carboxy termini indicated at the 
extracellular and intracellular ends of the protein, respectively. 
  
!
1! 2! 3! 4! 5! 6! 7!
NH2 
COOH 
Extracellular 
Intracellular 
Lipid 
Bilayer 
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Class Family Receptor Ligand Resolution (Å) Identifier 
A Adrenoreceptors β2-adrenoreceptor Carazolol and Nb60 
Carazolol 
Carazolol 
FAUC37 
BI167,107 
Hydroybenzyl isoproterenol 
Adrenaline 
Carazolol 
BI167,107 
BI167,107 
FAUC50 
ICI 118,551 
Compound 2 
Alprenolol 
Carazolol 
Timolol 
Carazolol 
Carazolol 
Carazolol 
3.2 
2.48 
3.8 
3.3 
2.79 
3.1 
3.2 
3.99 
3.2 
3.5 
3.5 
2,84 
2.84 
3.16 
3.4 
2.8 
3.4 
3.4 
2.4 
5JQH 
5D5A 
5D5B 
4QKX 
4LDE 
4LDL 
4LDO 
4GBR 
3SN6 
3P0G 
3PDS 
3NY8 
3NY9 
3NYA 
3KJ6 
3D4S 
2R4R 
2R4S 
2RH1 
β1-adrenoreceptor Cyanopindolol 
Salbutamol 
R-Isoprenaline 
Carmoterol 
Dobutamine 
Dobutamine 
Iodocyanopindolol 
Cyanopindolol 
Carazolol 
Cyanopindolol 
Carvedilol 
Bucindolol 
Cyanopindolol 
4-(Piperazin-1-yl)-1H-indole 
4-Methyl-2-(piperazin-1-
yl)quinolone 
Cyanopindolol 
2.7 
3.05 
2.85 
2.6 
2.5 
2.6 
3.65 
3.25 
3.0 
3.15 
2.3 
3.2 
3.5 
2.7 
2.8 
 
2.1 
2VT4 
2Y04 
2Y03 
2Y02 
2Y00 
2Y01 
2YCZ 
2YCX 
2YCW 
2YCY 
4AMJ 
4AMI 
4GPO 
3ZPR 
3ZPQ 
 
4BVN 
Opsin Rhodopsin Octylglucoside β-ionone 
-- 
Nonyl-glucoside 
Chromophore 
-- 
-- 
-- 
Arrestin 
Finger-loop peptide 
-- 
-- 
-- 
Arrestin 
-- 
-- 
2.7 
2.6 
3.4 
2.4 
2.8 
2.5 
2.9 
3.0 
3.3 
2.8 
2.6 
3.7 
2.8 
7.7 
2.7 
3.0 
4J4Q 
3OAX 
2J4Y 
4X1H 
1HZX 
2Z73 
3CAP 
3PXO 
4ZWJ 
4PXF 
1L9H 
2ZIY 
1F88 
5DGY 
3C9L 
2PED 
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Purine receptors A2A ZM241385 
UK-432097 
Adenosine 
ZM241385 
NECA 
XAC 
Caffeine 
ZM241385 
ZM241385 
4e 
4g 
ZM241385 
BRIL-ZM241385 
BRIL-ZM241385 
BRIL-ZM241385 
BRIL-ZM241385 
Mini-Gs 
BRIL-ZM241385 
BRIL-compound 12c 
BRIL-compound 12b 
BRIL-compound 12x 
CGS21680 
CGS21680 
6-(2,6-Dimethylpyridin-4-yl)-5-
phenyl-1,2,4-triazin-3-amine 
4-(3-amino-5-phenyl-1,2,4-
triazin-6-yl)-2-chlorophenol 
2.6 
2.71 
3.0 
3.3 
2.6 
3.31 
3.6 
2.7 
3.1 
3.34 
3.27 
1.8 
2.5 
2.5 
1.9 
1.9 
3.4 
1.72 
1.9 
2.0 
2.1 
2.6 
2.6 
3.27 
 
3.34 
3EML 
3QAK 
2YDO 
3PWH 
2YDV 
3REY 
3RFM 
3VG9 
3VGA 
3UZC 
3UZA 
4EIY 
5K2A 
5K2B 
5K2C 
5K2D 
5G53 
5IU4 
5IU7 
5IUA 
5IUB 
4UG2 
4UHR 
3UZA 
 
3UZC 
Dopamine receptors D3 Eticlopride 2.89 3PBL 
Histamine receptors H1 Doxepin(E,Z) 3.1 3RZE 
Muscarinic 
(acetylcholine 
receptors) 
M1 Tiotropium 2.7 5CXV 
M2 Iperoxo 
Iperoxo, LY2119620 
QNB 
3.5 
3.7 
3.0 
4MQS 
4MQT 
3UON 
M3 Tiotropium 
NMS 
Tiotropium-dsT4L 
Tiotropium 
2.8 
3.7 
3.6 
3.4 
4U15 
4U16 
4U14 
4DAJ 
M4 Tiotropium-T4L 2.6 5DSG 
5-Hydroxytryptamine 
receptors 
5-HT1B Ergotamine 
Dihydroergotamine 
Ergotamine 
Ergotamine 
2.7 
2.8 
2.7 
2.8 
4IAR 
4IAQ 
4IB4 
4NC3 
Angiotensin receptors AT1 ZD7155 
Olmesartan 
2.9 
2.8 
4YAY 
4ZUD 
Cannabinoid receptor CB1 AM6538 2.8 5TGZ 
Chemokine receptors CXCR4 IT1t 
IT1t 
CVX15 
IT1t 
IT1t 
vMIP-II 
2.5 
3.1 
2.9 
3.1 
3.2 
3.1 
3ODU 
3OE9 
3OE0 
3OE8 
3OE6 
4RWS 
CCR5 Maraviroc 2.7 4MBS 
Endothelin receptors ETB -- 
ET-1 
2.5 
2.8 
5GLI 
5GLH 
Free fatty acid 
receptors 
FFA1 TAK-875 2.3 4PHU 
Lysophospholipid 
receptor 
LPA1 ONO-9910539 
ONO-9780307 
ONO-3080573 
2.9 
3.0 
2.9 
4Z35 
4Z34 
4Z36 
S1P1 ML056 
ML056 
2.8 
3.4 
3V2Y 
3V2W 
Nurotension receptor NTS1 NT(8-13) 
LF-T4L 
ELF-T4L 
NT(8-13) 
NT(8-13) 
NT(8-13) 
NT(8-13) 
2.8 
2.6 
2.9 
3.6 
2.8 
3.0 
3.1 
4GRV 
4XES 
4XEE 
4BWB 
4BUO 
3ZEV 
4BV0 
Orexin receptors OX2 Suvorexant 2.5 4S0V 
OX1 Suvorexant 
Suvorexant 
2.8 
2.8 
4ZJ8 
4ZJC 
Proteinase-activated 
receptors 
PAR1 Vorapaxar 2.2 3VW7 
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P2Y receptors P2Y1 BPTU 
MRS2500 
2.2 
2.7 
4XNV 
4XNW 
P2Y12 AZD1283 
2MeSADP 
2MeSADP 
2.6 
2.5 
3.1 
4NTJ 
4PXZ 
4PY0 
B Corticotropin-
releasing factor 
CRF1 CP-376395 
CP-376395 
3.18 
2.98 
4Z9G 
4K5Y 
Glucagon receptor 
family 
Glucagon receptor NNC0640 
MK-0893 
3.3 
2.5 
4L6R 
5EE7 
C Metabotropic 
glutamate receptor 
mGlu1 FITM 2.8 4OR2 
mGlu5 Mavoglurant 
3-chloro-5-[6-(5-fluoropyridin-2-
yl)pyrimidin-4-yl]benzonitrile-
(HTL14242) 
3-chloro-4-fluoro-5-[6-(1H-
pyrazol-1-yl)pyrimidin-4-
yl]benzonitrile 
2.6 
2.6 
 
 
3.1 
4OO9 
5CGD 
 
 
5CGC 
F Frizzled SMO LY2940680 
Choesterol 
Vismodegib 
Cyclopamine 
SAG1.5 
SANT1 
Anta XV 
2.5 
3.2 
3.3 
3.2 
2.6 
2.8 
2.6 
4JKV 
5L7D 
5L7I 
4O9R 
4QIN 
4N4W 
4QIM 
 
Table 1.1 Solved GPCR crystal structures 
 
To date, crystal structures have been obtained for four of the six classes of GPCR. The PDB 
database accession numbers (identifiers) and level of resolution are provided for each 
structure. 
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Analysis of the crystal structures reveals that whilst GPCRs exhibit 
significant structural similarities there is a rich complexity across the different 
receptor subtypes. The generic GPCR structure consists of a membrane spanning 
region of hydrophobic amino acid residues, which are linked by three 
extracellular (ECL) and three intracellular (ICL) hydrophilic loops found on 
either side of the membrane, with the N-terminus protruding extracellularly and 
the C-terminus extending intracellularly[7]. The sizes of N-terminal, ECLs and 
C-terminal tails can vary dramatically among GPCRs. Each membrane-spanning 
region (TM domains) is comprised of alpha helices containing approximately 21 
to 28 amino acid residues [8]. A highly-conserved disulfide bridge is found 
between two cysteines residues in the extracellular loop II (ECL 2) in most 
GPCRs and the end of TM3 is key in maintaining the GPCRs structure. Viewed 
from within the plane of the membrane, a GPCR resembles a barrel shape where 
the 7TM helices form a cavity within the plasma membrane that serves a ligand-
binding domain that is often covered by ECL 2. Ligands may bind elsewhere as 
in class C GPCR where the binding domain is in the N-terminal tail itself. 
Despite this structural diversity, the binding pockets of GPCRs are rigid and 
undergo restricted conformational rearrangements during the activation 
process[9, 10]. A number of interhelical bonds and hydrophobic interactions 
between highly conserved residues in GPCRs have been found to impart the 
stability of the transmembrane region[4]. In fact, the 7TM helices are also 
comprised of functionally important signature motifs, including the E/DRY motif 
in TM3, which is part of the ‘ionic lock’, the WXP motif in TM6 and the 
NPXXY motif in TM7[10]. The helices also contain a number of kinks elicited 
by prolein residues, which segregate the receptor into ligand binding and 
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receptor signalling “modules” [9]. Another striking feature of GPCRs is that the 
extracellular loop between TM4 and TM5 and intracellular loop between TM5 
and TM6 are extended. The second extracellular loop contains a N-linked 
glycosylation point that functions in stabilizing the protein conformation, 
protection from proteases, and modulates the protein function[7].  The archetypal 
conserved amino acid residues in the α-helices across the whole GPCR 
superfamily are listed in Table 1.2. 
 
 
α-Helices Amino acid Amino acid identifier 
TM1 
TM2 
TM3 
TM4 
TM5 
TM6 
TM7 
Asn 
Asp 
Arg 
Trp 
Pro 
Pro 
Pro 
N 1.50 
D 2.50 
R 3.50 
W 4.50 
P 5.50 
P 6.50 
P 7.50 
 
 
 
Table 1.2 Signature amino acids within GPCR TMs 
 
Each TM contains an amino acid that is highly conserved across all members of the GPCR 
superfamily. These have been numbered using the Ballesteros-Weinstein method. 
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1.1.2 GPCR Signalling 
A central feature of GPCR signalling is that the extracellular ligand that 
binds to the receptor does not physically traverse the plasma membrane but 
conveys its signal to the cellular milieu through conformational changes in the 
receptor elicited upon ligand binding. GPCRs exist in two principal 
conformational states that are in equilibrium. One, an active conformation, 
initiates downstream events (R), whilst the other inactive conformation (r) is 
unable to do so, in the presence or absence of activating ligand (agonist). 
Typically, the binding of an agonist to the receptor provokes a switch from its 
inactive to its active conformation causing an increase in the proportion of active 
receptors, which opens up the helical bundle and exposes the binding site of the 
receptor where it interacts with its cognate G-protein at the cytoplasmic side of 
the plasma membrane. On the other hand, the presence of an antagonist binds to 
the inactive conformation (r) and stops signal transfer causing the reduction of 
the number of active receptors. The desensitization of the GPCR is initiated by 
its interaction with GRKs, or G protein-coupled receptor kinases, leading to its 
phosphorylation, usually at its carboxy-terminal end. This in turn elicits the 
binding of β-arrestins, which sterically hinder additional G protein-coupling and 
ensure the termination of the agonist response. Partial agonists can bind to both 
conformational states, but they cannot achieve maximum simulation[6, 7, 11-14]. 
 
GPCRs exerts their actions through guanidine triphosphate-binding 
proteins (GTPases) that were discovered by Rodbell, Gilman, and co-workers. 
These “G-proteins” are heterotrimeric entities consisting of three subunits Gα, 
Gβ, and Gγ. The heterotrimeric G protein activation of the effector is mediated 
by the Gα-subunit. The cycle of event begins with GTP displacement of GDP 
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and ends with GTP-hydrolysis to GDP at the Gα-subunit, which is catalysed by a 
GDP-GTP exchange factor (GEF). Binding of GTP causes a conformational 
change that causes the Gβγ-subunits dimer to dissociate from Gα-subunit. The 
dissociated G-subunits initiates input signal from membrane receptors to effector 
protein. The GTPase activity within the Gα-subunit causes the inactivation of the 
system and re-association of the heterotrimeric G-protein subunit[7, 15]. The Gα-
subunit is divided into four subtypes: Gαs, Gαi, Gαq/11, and Gα12/13. Two of these 
subtypes transduce the membrane receptor signal through the enzyme adenylate 
cyclase, Gαs stimulates it and increase the level of cAMP within cell, whereas 
Gαi inhibits the enzyme and reduces the intracellular levels of cAMP. Gαq/11 
subtype stimulates phospholipase Cβ that mediates the release of intracellular 
calcium from endoplasmic reticulum stores by hydrolysing phosphotidylinositol 
4,5-diphosphate (PIP2) into 1,2-diacylglycerol (DAG) and inositol 1,4,5-
triphosphate (IP3), and it includes several subgroups. The other α-subunit 
subtypes act on regulating the protein activity (see Figure 1.2)[7, 15]. 
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Figure 1.2 GPCRs intracellular signaling and downstream effects. 
 
1.2 GPCR oligomerisation 
For many years, the GPCRs have been viewed as monomeric entities, 
activating G proteins in a 1:1 ratio. This classical model of coupling is 
oversimplified, and many functional GPCR have been shown to exist as 
homodimers, heterodimers, or even as higher order oligomers[7, 16-18]. The 
description of GPCRs as homodimers or heterodimers refers to the physical 
coupling of two receptors in the cellular membrane to produce a functional 
centre with novel structural and functional characteristics, in comparison with the 
properties of each of the receptors on its own. Each receptor in the dimer is 
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termed a ‘protomer’. Homodimers are pairs comprised of identical protomers, 
while heterodimers are formed from distinct receptors. An oligomer is a 
multimeric protein formed from a small number of subunits in a state of 
reversible association with each other[19]. The interaction between these two 
receptors is defined as the binding of a ligand to the orthosteric or allosteric sites 
of one receptor, causing a modification in the ligand recognition, decoding and 
trafficking processes of another receptor via allosteric interactions[20]. 
 
  Early examples of oligomerisation include the obligate heteromeric 
assembly of GABABR1 and GABABR2 required to form a functional GABAB 
receptor[16] and the heterodimerisation of the delta and kappa opioid receptor 
subtypes to form an opioid receptor with the κ2 receptor subtype 
pharmacology[17]. Oligomerisation can occur between different types of 
receptors of different classes, for example dopamine receptors have been 
reported to oligomerise with the adenosine A2A receptor, the CB1 cannabinoid 
receptor, the metabotropic glutamate type 5 receptor (mGlu5) and the 
somatostatin-2 and -5 receptors[21-27]. The first physical proof of dimerisation, 
however, emerged from atomic-force microscopy analysis of the rhodopsin 
receptor which was shown to form structural dimers organised in paracrystalline 
arrays in the membrane[28] and in the model crystal structure of this GPCR 
(1N3M)[29]. 
 
The discovery that GPCRs are able to oligomerise has raised important 
questions as to where and how these complexes are formed and expressed at the 
cell surface. While oligomers can arise transiently in the plasma membrane in the 
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presence of agonists, reports have suggested that receptor dimerisation and the 
assembly of GPCRs with their signalling complex may occur early during 
biogenesis, prior to trafficking to the plasma membrane[12, 30] whilst other 
findings suggest that dimerisation depends on the receptor density[31]. Studies 
have indicated that molecular chaperones may contribute to the proper folding of 
receptors as well as the assembly of signalling complexes, indicating that these 
complexes may be delivered to the plasma membrane as “complete signalling 
units”[12]. The literature of receptor oligomerisation suggests that dimerisation 
can occur in the endoplasmic reticulum (ER) or during protein maturation in the 
Golgi apparatus, which might play a role in the ER quality control and exit by 
masking the ER-retention motifs of some receptor sequences[12, 32-34]. In 
support of this idea, it has been shown that the dimerisation of group I 
metabotropic glutamate receptor (mGluR1α) must take place in the ER[35]. 
Moreover, studies have established that oligomerisation has important effects on 
receptor function, including ligand binding, activation, desensitization, and 
trafficking, as well as signalling[36-38]. 
 
1.3 Experimental determination of oligomerisation 
In the early 1990s, with advances in the biochemical and biophysical 
techniques, it became possible to detect the presence of dimeric GPCRs entities. 
Biological methods for studying GPCR oligomers in native cells and tissues or in 
recombinant mammalian expression systems include co-immunoprecipitation 
(CoIP), Western blot analyses, cross-linking studies, yeast two hybrid 
experiments, bi-molecular fluorescence complementation via GFP reconstitution 
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(BiFC), energy transfer-based methods (FRET and BRET), photobleaching 
FRET (pbFRET), sequential BRET/FRET (SRET), functional cross-talk and 
activation by dimeric/bivalent ligands. Table 1.3 provides examples of 
homo/hetero GPCR dimers entities that were identified by these biological 
methods. Due to diversity in both primary sequences and in the structural 
features of GPCRs, not all methods are applicable for the detection of a dimer 
under stimulated or un-stimulated conditions[39] and the results of GPCR 
dimerisation shown in Table 1.3 were obtained using different experimental 
approaches. Unfortunately, these methods do not always discriminate between 
proteins in close proximity and those that physically interact, something that has 
frequently allowed for alternative interpretations of the results and, therefore, has 
made it difficult to obtain unequivocal answers about the occurrence of 
multimerization between candidate pairs of GPCRs. In addition, contrasting 
results for the same GPCR pairs have been obtained using different experimental 
techniques. For example, the chemokine receptor CCR5 was found to form an 
agonist-dependent dimer using the biochemical cross-linking method[40] whilst 
using the BRET method on the same receptor it was shown to form a constitutive 
dimer during biosynthesis with no change in the intensity of BRET was observed 
upon agonist binding[41]. In some studies it has been reported that the 
cytoplasmic tail of a GPCR is essential for dimerisation of the receptor. For 
instance, a mutated δ-opioid receptor with a 15-residue C-terminal deletion does 
not show interactions as it fails to exhibit CoIP with two differently tagged 
receptors[42] but in other studies, the C-terminal portion of a GPCR has been  
shown to have no effect receptor dimerisation. As an example, the dimerisation 
of the H2 histamine receptor does not involve its C-terminal portion[43]. It is a 
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further complication that these techniques do not yield specific details of the 
interface(s) between interacting GPCRs, something that would provide a 
capacity for further analysis of identified dimerisation through site-directed 
mutagenesis studies. Structural methods such as x-ray crystallography and 
atomic force microscopy could provide this information, however, when this 
project commenced, only one GPCR dimer structure had been solved and 
described “contact areas” rather than molecular interfaces[44]. 
 
GPCR dimers Biological methods used to investigate receptor association Reference 
Heterodimers (a) between family subtypes 
GABAB1:GABAB2 TR-FRET-HTRF using Snaptag or antibodies [45] 
δ:κ SDS-PAGE [17] 
D1:D2 CoIP, confocal microscopy, BiFC [46-49] 
D1:D3 FRET, confocal microscopy, BiFC [50] 
A2A:A1 CoIP, BRET, TR-FRET [51] 
P2Y1:P2Y11 CoIP, FRET [52] 
Heterodimers (a) between different receptors 
A2A:D2 BiFC, FRET, CoIP, Immunofluorescence microscopy [21, 53] 
D2:SSTR5 Immunohistochemical colocalization, confocal microscopy, FRET [27] 
D2:CB1:A2A BiFC, BRET, sequential BRET-FRET (SRET), confocal microscopy  [54-56] 
A2A:CB1 Colocalization, CoIP, BRET [57] 
A2A: mGlu5 CoIP [58] 
mGlu5:A2A:D2 Colocalization, CoIP, BiFC, BRET and SRET [59] 
mGlu2A:5-HT2A  BRET, CoIP, colocalization [60] 
A1:P2Y1 CoIP, confocal microscopy, BiFC [61-63] 
Homodimers 
A2A CD spectroscopy and SDS-PAGE [64] 
β2-Adrenergic CoIP,  western blot, BRET, functional complementation  [65-69] 
CCR5 Cross-linking,  western blot, yeast two-hybrid analysis, BRET,  dominant 
negative  
[40, 41, 
70, 71] 
κ Western blot , BRET [17, 72] 
H2 CoIP [43] 
M3 CoIP, western blot [73] 
 
Table 1.3 Experimentally-identified homo/heteromeric GPCRs 
 
Homodimer formation has been detected in at least six different receptor family GPCRs and 
heterodimer formation has been identified between receptor family subtypes and between 
different receptor families using a number of different experimental techniques.   
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1.3.1 Bimolecular Fluorescence Complementation 
Since protein interactions regulate many cellular processes, it is of great 
importance when exploring the function of a protein to identify if there are other 
proteins with which it interacts[74, 75]. The discovery of a green fluorescent 
protein (GFP), composed of 238 residues, from Aequorea Victoria in 1962[76] 
has provided valuable information to our understanding of protein interactions as 
well as to they way in which they modulate cellular events[74]. GFP has become 
well-established as a marker of gene expression and protein targeting in intact 
cells and organisms[77]. 
 
GFP has been used in a protein complementation approach developed to 
directly visualize the protein-protein interaction within living cells. The 
bimolecular fluorescence complementation technique is based on the fact that 
two non-fluorescing fragments of GFP can reassociate to reconstitute the GFP 
protein, restoring fluorescence (see Figure 1.3)[75]. The dissection and 
subsequent reassembly of a protein from peptidic fragments provides a 
possibility for controlling its tertiary structure and hence its function[78]. The 
GFP is used preferentially as it is known to express, fold, and fluoresce in 
virtually every type of cell and subcellular structure in which it has been 
tested[75]. There are a large number of variants of GFP, including yellow and 
cyan fluorescent proteins all of which are able to reassociate and form functional 
fluorescent proteins when their dissected non-fluorescent fragments are brought 
into sufficiently close proximity[79]. 
 
Subsequently, the protein complementation approach was applied to the 
visualization of protein-protein interactions and to study the interaction of 
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multiple proteins in living cells. This was achieved by making fusion proteins 
between two target proteins of interest and different GFP variant fragments. 
Reassembly of the GFP fragments produces fluorescence when the complex is 
excited by light at the wavelength needed to visualize the variant’s fluorescence. 
The bimolecular fluorescence complementation (BiFC) assay is a multicolored 
BiFC assay that uses an enhanced yellow fluorescent protein (EYFP) and an 
enhanced cyan fluorescent protein (ECFP)[80]. 
 
 
 
 
 
Figure 1.3 Mechanism of the GFP reassembly screen 
Most of the fusions to the GFP fragments are insoluble. Interaction between the individual GFP 
fragments only occurs if they are fused to interacting proteins. Reassembly is essentially 
irreversible, which effectively pulls more of the fusions into solution. 
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However, EYFP has one limitation involving the chromophore 
maturation sensitivity to higher temperatures[77], which requires pre-incubation 
of cells at lower temperatures prior to visualizing the BiFC signal. Unfortunately, 
the decrease in temperature itself is a stressful condition[79, 81]. This difficulty 
prompted the discovery, by Shyu et al. in 2006, of several new fluorescent 
protein combinations able to work under physiological conditions. The new 
BiFC partners eliminate the need for pre-incubation at lower temperatures, show 
higher specificity, require lower amount of plasmids for transfection and have a 
shorter incubation time, leading to the increase of both the BiFC signal and its 
specificity[80]. 
 
The new BiFC partners consist of the N-terminal fragment of Cerulean 
from residues 1-172 (N173)[82] and the C-terminal fragment of Venus from 
residues 155-238 (C155). Cerulean is an improved ECFP mutated at 
(S72A/Y145A/H148D), which shows a 2.5-fold increase in fluorescence 
intensity compared with ECFP. Venus[83] is a new YFP mutant 
(F46L/F64L/M153T/V163A/S175G) engineered to be less sensitive to the 
environment[80].  
 
The BiFC-fusion receptors can be studied using both stable and transient 
expression techniques. The advantages of the BiFC assay include, first, a high 
level of receptor expression is not a requirement, and therefore, it allows the 
detection of weak interactions between proteins. Secondly, the simple detection 
of the reconstituted fluorescent protein process using a fluorescent microscope 
because it has a strong intrinsic fluorescence, which allows direct visualization of 
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the protein complex under circumstances where agonist and antagonist can be 
applied and the results on protein-protein interactions are observed also make 
this technique more favorable[84]. One limitation of the BiFC approach is the 
time required for fluorophore maturation. This prevents real-time detection of 
rapid changes in interactions. In addition, bimolecular fluorescent complex 
formation is irreversible in vitro. 
 
1.3.2 GPCR oligomerisation studied using BiFC 
 The occurrence of GPCR oligomerisation is now very well documented 
and widely accepted. Most techniques for the detection of GPCR oligomers only 
allow the detection of protein-protein interactions, but combining the BiFC and 
FRET/BRET techniques in multiple ways was established to measure ternary or 
quaternary higher ordered complexes[85]. The physiological and 
pharmacological significance of the higher-order GPCR complexes remains to be 
fully elucidated as these complexes may offer new drug targets. 
 
 Higher order GPCR oligomers were identified by this technique. The well 
documented A2AR receptor homodimer[86] was found to assemble into higher 
order oligomers by the use of a combined BiFC-FRET and BiFC-BRET 
technique[87, 88]. In another example, the interaction between D2R and 
A2AR[89], which was also confirmed by BiFC measurements in a neuronal cell 
mode[90], were also shown to form higher order oligomers[85]. Experiments 
using a combination of BiFC and biomolecular luminescence complementation 
(BiLC) have demonstrated the existence of homomeric D2R complexes with four 
protomers[91]. 
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1.4 Computational analyses of GPCR interactions 
There have been many computational studies of GPCR interactions (see 
Table 1.4). The methodologies for modelling these have, in general, adopted one 
of two approaches: (i) molecular dynamics simulations using models based on 
homology with the nearest related GPCR for which structural data exist or (ii) 
docking[92, 93]. Initial GPCR MD studies were performed using CHARMM and 
AMBER which were subsequently integrated into NAMD[94, 95] and 
GROMACS[96, 97]. Although there is no established standard protocol for MD 
simulations of GPCRs, a number have used GROMACS with the Martini force 
field[98-103], which is designed specifically for lipids and membranes and 
allows the lipid composition most suited to the receptor in question to be 
incorporated into the simulation. The more recent of the GPCR dimer modeling 
studies have been conducted using coarse-grained simulations, which take less 
compute time and, therefore, provide an opportunity to perform a substantial 
number of replicas for each set of simulation conditions. 
 
There is currently no standard protocol for the computational study of 
GPCR helix-helix interactions. By 2015, approximately 30 computational GPCR 
dimer models had been published (see Table 1.4). Of these, 2 are Monte Carlo-
derived, 15 are based on docking and 9 have been generated using atomistic MD 
simulations. The rest are CG-MD models. Historically, docking was the earliest 
method to be employed and has been used regularly; its current use is 
widespread. Alternative methods of modelling began with Monte Carlo methods, 
moving to fully atomistic MD, with a subsequent shift to CG-MD, which is the 
predominant MD method currently in use. CG-MD is popular as it is cheaper, 
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faster and has been shown, when CG models are subsequently converted to 
atomistic representations, to produce similar results as models generated by 
atomistic MD[100, 104, 105]. CG-MD simulations have also been used to study 
TM helix-helix dimers for non-GPCR types of cell surface receptors such as 
GpA and ErbB dimers[106, 107].  
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Type GPCR dimers Method Force field Interface Number of replicas Time scale Reference 
Homodimers Rho/Rho Docking CVFF TM4,5/TM4,5 
 
TM1,2/TM1,2 
 100 ps 
ND* 
ND 
[108] 
[109] 
[110] 
MD Gromos-87 
OPLSAA 
Amber/parm99 
TM4,5/TM4,5 
 
1 
1 
2 
45 ns 
0.1 µs 
300 ns 
[111] 
[112] 
[113] 
CG-MD Martini TM1,2, H8 
TM4,5/TM6,7 
1a  
10 
8 µs 
100 µs 
[98] 
[114] 
β2-/β2-adrenergic CG-MD Martini H8/H8 
TM1/TM1 
TM4,5/TM4,5 
TM5/TM5 
TM6/TM6 
TM3/TM3 
2 
4 
1b 
5 µs 
~200 µs 
~18 µs 
[103] 
[102] 
[101] 
β1-/β1-adrenergic CG-MD Martini TM1/TM1 
TM5/TM5 
3c (2 runs different 
starting point) 
2 µs [101] 
α1B-/α1B-
adrenergic 
Docking  TM5/TM5 
TM6/TM6 
TM7/TM7 
 ND [115] 
5-HT4/5-HT4 Docking  TM2,4/TM2,4 
TM4,6/TM4,6 
 ND 
 
[116] 
[117] 
[118] 
5-HT1A/5-HT1A Docking CHARMM TM4,5/TM4,5  15 ns [119] 
CXCR4/CXCR4 Docking  TM4,5,IL2/TM4,5  ND [110] 
MD OPLSAA TM3/TM4,5 
TM5/TM5 
1 50 ns [120] 
NTSR1/NTSR1 Docking CHARMM TM1/TM4 
TM4/TM4 
 ND [121] 
δ-OR/δ-OR CG-MD Martini TM2,3,4/TM2,3,4  1d  250 ns [99] 
TM4/TM4 favored 
over TM4,5/TM4,5 
2 1.5 µs [122] 
κ-OR/κ-OR Docking  TM1/TM2  ND [110] 
A2AR/A2AR Docking CHARMM TM1,2,3/TM1,2,3 
TM1/TM1 
TM1,4/TM1,4 
TM2,3/TM2,3 
TM6,7/TM6,7 
H8,I3/TM6 
 ND [123] 
A3R/A3R MD Amber7 FF99 TM4,5/TM4,5 1 500 ps [124] 
TXA2/TXA2 Docking  TM1/TM1 
TM1/TM2,EL2 
H8/H8 
 ND [125] 
D2R/D2R Monte 
Carlo 
 ND  ND [126] 
SSTR1/SSTR1 Monte 
Carlo 
 ND  ND [126] 
LHR-LHR Docking  TM4/TM6,7  ND [125] 
MD CHARMM TM4/TM4 
TM4/TM6 
TM5/TM6 
TM4/TM1,3 
1 1 ns [125] 
Heterodimers A2AR/D2R Docking  TTM3,4/TM5,6 
TM3,4,5/TM4,5 
TM4,5/TM3,4,5 
 ND [22] 
mGluR2/5-HT2A Docking  TM4,5/TM4,5  ND [95] 
MD CHARMM22/2
7 
TM4,5/TM4,5 1 40 ns [95] 
µ-OR/δ-OR Docking  TM6,7/TM4,5 
TM1,7/TM4,7 
 ND [127] 
MD GROMOS87 TM1,7/TM4,5 
TM4,7/TM4,5 
1 5 ns [127] 
Homotetramer (V2R)4 MD CHARMM22/2
7 
TM3,4/TM4,7 
TM4,5/TM4,5 
1 5 ns [94] 
 
Table 1.4 Computational methods for modelling GPCR dimers 
 
Summary of the computational methods used for modeling mammalian GPCRs to date. * ND: 
Not defined, IL: intracellular loop, EL: extracellular loop; a 4 different structures; b 9 different 
structures; c 2 runs, different starting point; d umbrella sampling of 43 different starting points. 
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1.5 Effects of GPCR oligomerisation 
 Oligomerisation affects and provides a network of novel and diverse 
functions within cells. Heterodimerisation is able to alter the agonist affinities of 
individual receptors, thus generating entities with novel agonist and antagonist 
pharmacologies, for example, within the purinergic receptor family, the A1R-
P2Y1 association provoked an A1R with P2Y1R-like agonist patterns[62]. For 
two other rhodopsin-like Class A GPCRs, the β-AR and AT1R dimer provides an 
example of cross-inhibition, whereby the blockade of one protomer results in the 
uncoupling and inhibition of its interacting partner[128, 129]. It can also modify 
the selectivity of GPCRs for distinct G-protein subsets by changing the 
downstream signalling cascades; for example, the D1-D2 heterodimer couples to 
Gq/11, leading to PLC-mediated intracellular calcium increase, a pathway that is 
not observed for the D1 or the D2 receptors[46, 47]. Lastly, it might regulate 
desensitization and trafficking mechanisms by potentiating the internalization of 
receptors that cannot internalize on their own. For instance, the dimerisation of 
the µ- and δ-opioid receptors provokes the cross-internalization of the µ-opioid 
upon activation of δ-opioid, thus reducing µ-opioid receptor-induced analgesia 
[12]. 
 
 The wide-ranging effects of GPCR oligomerisation upon cells means that 
there is huge potential to expand the number of targets for which new therapies 
can be designed. Novel therapeutic design is also important if one of the goals of 
personalized medicine, to develop new drugs for patient-specific variations of 
GPCRs, is to be achieved. Inclusion of functional GPCR homomers and 
heteromers in drug discovery programmes also provides a means of expanding 
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the range of novel targets for the development of therapeutic agents[37]. The 
development of therapeutic agents for purinergic GPCRs is of particular interest. 
 
1.6 Purinergic receptors  
Purine receptors, also referred to as purinergic receptors, are a subfamily of 
GPCRs that mediate cell signalling across the plasma membrane following 
activation by nucleoside and nucleotide analogues. In 1978, Burnstock et al. 
suggested that although structurally similar, these receptors should be divided 
into two distinct subfamilies based on their agonist selectivity: the P1 and P2 
receptors. P1 receptors subtypes include A1, A2A, A2B and A3 and are activated 
by the nucleoside adenosine, whilst P2 receptors are activated by nucleotides, 
including adenosine/adenosine 5`-triphosphate (ATP), adenosine 5`-diphosphate 
(ADP), uridine 5`-triphosphate (UTP), and uridine 5`-diphosphate (UDP). The 
structures of these related agonists are shown in Figure 1.4[8]. P2 receptors can 
be further divided into two subtypes, P2X and P2Y, and can be further classified 
based on their different response profiles to ATP analogues and selective 
antagonism. There are eight P2Y subtypes, all of which are GPCRs: P2Y1, P2Y2, 
P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14[1, 130-132]. 
 
The transmembrane domains of the P1 adenosine receptors share 11-18% 
sequence identity with the P2Y receptors[133]. The P2Y receptors contain 
between 308 to 377 amino acid residues, with positively charge amino acids in 
TM3, TM6, and TM7 regions that have been shown to be involved in ligand 
binding. Two distinct P2Y receptor subgroups have been identified. The first 
group includes P2Y1, 2, 4, 6, 11 and the second group includes the P2Y12, 13, 14. These 
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differ in their primary coupling to transductional G proteins. The first subgroup 
use the Gq/11 to activate the Phospholipase Cβ, causing the formation of inositol 
1,4,5-triphosphate and the release of intracellular calcium, whereas the second 
couples to members of the Gi/o family of G proteins[131, 134]. The P2X 
receptors are structurally unrelated to the P2Y receptors, although frequently 
activated by the same nucleotides. P2X receptors are membrane ion channels that 
open in response to the binding of extracellular nucleotides. Seven genes in 
vertebrates encode the P2X receptor subunits, which are 40–50% identical in 
amino acid sequence. Each subunit has two transmembrane domains, separated 
by an extracellular domain about ∼280 amino acids and channels form as 
multimers of several subunits[135]. 
 
Early studies identified that the purinergic receptors are frequently co-
expressed in different proportions and different tissues. Within a receptor family, 
individual subtypes can form homodimers or heterodimers, something that has 
important implications for drug development[136]. 
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Figure 1.4 The structure of P1 and P2 receptor agonists  
The nucleoside adenosine is the endogenous activator for all P1 receptors, whereas the 
nucleotides ADP, ATP, UDP and UTP activate P2 receptors.  
 
 
 
1.6.1 The P1 Receptors 
The P1 receptors belong to the Class A rhodopsin-like family of GPCRs. 
They have a short N-terminus of ~7 to 13 amino acid residues and a larger C-
terminus of ~32 to 120 amino acid residues[133]. They have been subdivided 
into the four different subtypes according to their distinct molecular structures, 
tissue distributions, biomedical, and pharmacological evidence. Each of A1, A2A, 
A2B, and A3 contains an intron within the coding sequence that is located at the 
end of third transmembrane domain. These four subtypes play an essential role in 
responding to adenosine in the central nervous system, regulating pain, cerebral 
blood flow, basal ganglia functions, respiration, and sleep. It is of great 
Adenosine 
ADP 
ATP 
UDP UTP 
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importance to develop more selective compounds for the P1 receptor-subtypes as 
this could provide therapeutics for treating numerous human diseases, such as 
pain, Parkinson’s disease, Huntington’s disease, asthma, seizures, and many 
other neurological disorders[137]. 
 
The transmembrane domains of the human P1 adenosine receptors share 
39-61% sequence identity with each other[133]. The first cDNAs encoding the 
A1 and the A2A receptor subtypes were isolated in 1989 by Libert and co-
workers[138]. The P1 receptors couple primarily to adenylate cyclase[131]. The 
A1 and A3 subtypes couple negatively to adenylate cyclase through Gi/o protein 
alpha subunit. The A2A and A2B subtypes couple positively to cAMP through the 
Gs protein. A2B has been observed to couple to through Gq/11 to regulate 
phospholipase C activity[133]. 
 
 
1.6.2 The A2A Receptor 
The A2A receptor has the highest molecular weight of all the P1 receptors, 
45 kDa compared to 36 to 37 kDa for the other adenosine receptors. Its large C-
terminus domain has no effect on the coupling to Gs protein, which is mediated 
by the N-terminal portion of the third intracellular loop, nor does it effect the 
ligand binding[139]. 
 
A2A has been cloned from several species including human, rat, mouse, 
and guinea-pig. The human gene for the A2A receptor has been mapped to 
chromosome 22 at 22q11.2 and contains two exons and a 6-7.2 kb long intron 
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between the regions encoding TM3 and TM4, corresponding to the second 
intracellular loop of the receptor[131, 138]. The human A2A receptor is 
polymorphic, containing two nucleotide differences, a substitution of T for C at 
the third base of codon 361 (nucleotide 1083) and a substitution of G for A at the 
first base of codon 392 (nucleotide 1174) which gives rise to a change from Arg 
to Gly at residue 392; the T1083C mutation is a silent mutation that is found in 
various populations most frequently in Asians and Caucasians[138, 140]. 
 
The A2A receptor distribution is well understood due to studies performed 
with a number of tools including radioligand binding, in situ hybridisation and 
immunohistochemical studies. Radioligand binding and mRNA quantification 
show A2A receptors to be concentrated in the dopamine-rich regions of the brain. 
They have a wide but restricted distribution with diverse biological effects in 
other tissues, including immune tissues, platelets, striatopallidal GABAergic 
neurons, olfactory neurons, central nervous system, spleen, thymus, endothelium, 
and vascular smooth muscle[131, 138]. 
 
The most commonly recognized signal transduction mechanism for A2A 
receptors is through positive activation of adenylate cyclase mediated via couple 
to the Gs protein[131]. It has also been suggested that the A2A receptor mediates 
dual signalling via P- and N-type Ca2+ channels linked to Gs / adenylate cyclase / 
phosphorkinase A (PKA) and cholera toxin-insensitive G-protein/PKA, 
respectively (see Figure 1.5)[141]. 
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Figure 1.5 Signalling pathway for the A2A receptor 
Coupling of the A2A receptor to the Gas protein leads to the accumulation of intracellular levels of 
cAMP produced through activation of the enzyme adenylyl cyclase. 
 
 
The A2A receptors are activated by the endogenous ligand, adenosine, and 
by adenosine analogues modified at the C2 position of the purine ring. Bulky 
substitutions at C2 can selectively enhance receptor affinity and have been used 
to characterize A2A receptors.  The A2A receptors do not bind N6-substituted 
adenosine derivatives with high affinity. The most selective A2A agonist is CGS 
21680; other selective agonists include: HE-NECA, CV-1808, CV-1674, 
ATL146e, and CVT-3146. A2A receptor antagonists include: SCH 5826, 
ZM241385, KF 17387, CSC, SCH58261, and KW 6002, where the SCH 5826 is 
a selective A2A antagonist, and ZM241385, KF 17387, CSC are moderately 
selective antagonists[142]. 
!
!
!
!
!
!
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1.6.3 Structure of the A2A receptor  
 The first crystal structure of the A2A receptor in complex with antagonist 
ZM241385 was achieved using an A2A-T4-lysozyme fusion (3EML)[137]. This 
structure revealed some unique features that were distinct from the other 
available GPRC structures at that time, including: 1) a different organization of 
extracellular loops where the surface properties of the receptor are dictated by 
ECL-2; 2) an extended conformation of ligand binding pocket towards the 
extracellular space; and 3) a subtle divergence of helical positions that redefined 
the receptor’s binding site. This demonstrated that the ligand-binding pocket was 
located in a different position and orientation relative to other GPCRs and that 
ligand selectivity could be achieved through targeting hydrophobic residues 
extending from the aromatic core[2]. 
 
In the A2A receptor structure, the ligand-binding pocket was found to be 
shifted towards the extracellular side compared to that of bovine rhodopsin, 
β1AR, and β2AR[4, 6, 137, 143]. It is closer to transmembrane VI and VII where 
the agonist and antagonist binds in an extended conformation perpendicular to 
the plane of the membrane and co-linear with transmembrane helix VII, while 
interacting with both ECL-2 and ECL-3. The D/ERY motif of the A2A adenosine 
receptor participates in the interactions that restrain the conformation of ICL-2, 
as in β1AR and β2AR structures, and it plays a role in stabilizing the 
deprotonated state of the adjacent aspartate or glutamate residue that can 
strengthen the polar interactions between the ICL-2 and helix II with the D/ERY 
motif[137]. 
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1.6.4 A2A receptor oligomerisation 
Transmembrane (TM) domain interactions are a major determinant in the 
assembly and stability of the native structure of membrane proteins. It has been 
proposed that for proteins traversing the plasma membrane several times, the 
helix-helix interactions need to be controlled to give rise to the final TM protein 
structure[144, 145]. The existence of these specific interactions shown to give 
rise to an increase in helical content, especially in weakly helical TM domains, 
suggesting that some TM domains need a partner for complete folding in the 
membrane[146]. Therefore, many of the α-helices inserted into a lipid bilayer 
might interact to form a helix-helix dimer and, subsequently, form interactions 
that give rise to the formation of a higher-ordered oligomeric structure. It is these 
interactions affecting the packing, hydrogen bonding, aromatic interactions and 
salt bridges formation that will determine the sequence specific packing of the 
TM helices into single-span, or multi-span TM proteins[145]. 
 
The A2A adenosine receptor subtype has been shown to participate in the 
formation of heteromeric[22], homomeric[86] and even higher ordered 
oligomeric GPCRs[87]. The identification of heterodimeric A2A with several 
different GPCRs has been documented, including heterodimers formed with the 
A1[51], dopamine D2[22, 53], cannabinoid CB1[57] and metabotropic glutamate 
(mGlu5) receptors[58]. A2A receptor homodimers form through specific 
interactions between TM helices, leading to an increase in helical content. This 
has been shown to take place specifically at the weakly helical TM domains, 
suggesting that the helix-helix interactions, in addition to the helix-lipid 
interactions, facilitate homodimer formation. It has also been shown that TM 
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peptides interact in a similar fashion in micelles and lipid vesicles, which is not 
unsurprising as they exhibit thermal stability and α-helicity when inserted in SDS 
micelles similar to that observed when they are embedded in liposomes.  
 
A2A receptor homodimerisation has been experimentally demonstrated 
using several different techniques[64, 86, 147]. Seven strong specific interactions 
have been identified between synthetic peptides corresponding to the TM 
domains of the human A2A receptor; these interactions were identified before 
high resolution crystal structure data became available for GPCRs and were 
shown to be consistent with data that had been obtained for the three-
dimensional structure and stability of rhodopsin and the β2 adrenergic receptor 
using a combination of FRET measurement and circular dichroism (CD) 
spectroscopy in detergent micelles[146]. In 2005, interactions between the 
human A2A receptor TM domains were studied in pairwise combinations[147] 
and A2A receptor homodimerisation was shown to be mediated by the TM5 α-
helices of the two protomers[64, 147]. These data yielded a CD spectroscopy 
(Φ)222/(Φ)208 ratio > 1 for TM5-TM5 peptides, a ratio that is often associated 
with coiled coils or other assemblies of helical peptides. Further, it has been 
shown that the methionine at position 5.54 in TM5 of the A2AR receptor (M193) 
influences this homodimerisation. It was also reported that none of the known 
motifs for TM helix dimerization (GxxxG, AxxxA, SxxSSxxT, polar clamp, 
serine zipper, leucine zipper) appears in TM5. However, statistical analysis of 
amino acid patterns in TM helices using TMSTAT reveals that the PM4 pair 
(PxxxM) is the most overrepresented doublet pattern from any combination of 
PxxxX doublet pattern[64, 148]. In addition, it has been shown that the A2A C-
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terminal domain required for heterodimerisation[22] with the dopamine D2 
receptor is not involved in A2A homodimerisation. In 2008, bimolecular 
fluorescence complementation (BiFC) in Cath neuronal cells confirmed the 
specificity of the A2A - A2A interaction and by combining the FRET and BiFC 
techniques it has been shown that at least three A2A receptor protomers are able 
to assemble into a higher-order oligomer at the plasma membrane[87]. The major 
species of the A2A receptor present on the cell surface is in the dimeric form, 
making homodimers the functionally relevant form of this GPCR[86]. 
 
1.6.5 Class A GPCR dimers 
  Two models of dimerisation for transmembrane proteins are described 
in the literature. In the first, two protomers touch each other; leading to the 
formation of a contact dimer.  This has been established through the 
identification of rhodopsin dimers[28, 29], although these findings have been 
expressed in terms of contact areas rather than elucidating the precise molecular 
interactions at the dimerisation interface. In the second model, the hinge loop of 
the dimer opens, causing the domains to exchange and produce a domain-
swapped dimer[149]. Structural methods such as x-ray crystallography and 
atomic force microscopy have been used to provide information about GPCR 
structure, but only three Class A GPCR dimer structures have been solved to 
date: rhodopsin, CXCR4 and β1 adrenergic receptor (β1AR)[44, 150, 151].   
 
 Rhodopsin has been shown to exist in a native oligomeric form[29] and an 
atomic model of the rhodopsin dimer has been proposed as a working model for 
G protein-coupled receptor dimers[28].  The rhodopsin model (1N3M) was 
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resolved using atomic force microscopy (AFM) and suggests that rhodopsin 
dimers have three contact areas. The distance between the two-rhodopsin 
molecules measured by luminescence resonance energy transfer was 4-5 nm. 
According to the model, the first contact point is between TM4, TM5 and has the 
largest contact area of 578Å2; this is considered the strongest interaction between 
the two protomers. The second contact point between is located between TM1, 
TM2 and the intracellular loop connecting TM5 and TM6 (ICL-3) and covers an 
area of 333Å2. The third contact point is found at the extracellular ends of TM1 
with a contact area of 146Å2; this is considered the weakest interaction in the 
homodimer[28, 44]. 
 
  The crystal structure of the CXCR4 chemokine receptor (3ODU) 
bound to an antagonist small molecule IT1t has been reported and reveals a 
homodimer with an interface involving TM helices 5 and 6. This dimer is 
reported to be held together by hydrophobic interactions involving amino acid 
residues L1945.33, V1975.36, V1985.37, F2015.40, M2055.44 and L2105.49[150]. 
 
  Two alternating dimer interfaces have been proposed from the crystal 
structure of the ligand-free basal state of the β1AR (4GPO). The first involves 
TM1, TM2, extracellular loop 1 and the C-terminal H8; the second involves 
TM4 and TM5 and the intracellular loop 2. In the first dimer interface, the TM1-
TM2-H8 dimer, the interactions identified within the TM helices are mainly 
through TM1 and the interacting residues include Q381.29, Q391.30, A421.33, 
L461.37, L491.40, L501.41, V521.43, L531.44 and L541.45 (from TM1) and P962.59, 
A992.62, T1002.63 and V1032.66 (from TM2). These are proposed to be mainly 
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hydrophobic and van dar Waals interactions. The second dimer interface includes 
residues from both TM4 (L1714.44) and TM5 (R2055.36, A2065.37, A2105.41, 
I2185.49 and R2295.60)[151]. 
 
1.7 Molecular modelling and computational design 
High quality 3D computationally designed GPCR models are of critical 
importance as GPCRs are targets for drug design. Many structure-based 
methodologies have been developed to help identify novel pharmacological 
targets, by measuring the drug-ability of cavities, and also for discovering new 
bioactive molecules. The GPCRs, in particular, are structurally diverse especially 
at the ligand binding sites[152]. 
 
Computational design can be broadly divided into two classes: ligand-
based design and structure-based design[153, 154]. The structure-based approach 
uses the three-dimensional structure of the target. By far, the largest and most 
reliable source of protein structures is the Protein Data Bank (PDB)[155]. 
Membrane proteins are particularly difficult to crystallize because they display 
multiple thermodynamic conformations, which greatly complicates their 
extraction from membranes in order to generate crystals[156].  Like most 
membrane proteins, the GPCRs are extremely difficult to crystallize, and only a 
couple of these protein receptors have been crystallized and their structures 
deposited into the protein bank database today[157]. 
 
In ligand-based drug design, the characteristics of known ligands are 
evaluated, and then virtual screening of large databases of molecules is 
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performed in order to find compounds that bear resemblance in structure with the 
desired effect.  Due to the difficulty of crystallizing GPCRs, the generation of 
models of unknown structures from known crystal structures to assist in the 
study of these GPCR proteins is ideal. This is performed by a technique called 
homology modelling that compares unknown structures to similar known protein 
structures. Homology modelling coupled with molecular dynamics provides 
insight into the behaviour of proteins of unknown structure within the cells. 
 
1.7.1 Molecular Dynamics 
Computer simulations, in general, act as a bridge between theory and 
experiment. Computer simulations are usually performed to assist our 
understanding of the properties, structures, and microscopic interactions between 
the assembled molecules. They are mostly used as a complement to support or 
interpret the findings of well-established experiments, and to enable us to 
generate new findings that can be tested experimentally. Theories can be tested 
by conducting a simulation using an in silico version of the experimental model, 
in silico models can be compared with experimental results and simulations can 
be performed computationally that are difficult or impossible to perform in the 
laboratory, for example,  working at extremes of temperature or pressure. 
 
There are two main families of simulation techniques: Molecular 
dynamics (MD) and Monte Carlo (MC). Molecular dynamics simulations consist 
of the numerical, step-by-step, solution of the classical equations of Newton’s 
law of motion (1) in computational chemistry to describe ensembles of the 
movement of atoms and molecules. The major use of molecular dynamics 
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simulations in biological modelling is to study the behaviour of macromolecules 
in solution or within the membranes in lipid bilayer systems[158]. 
 𝐹 = 𝑚  𝑎                          (1) 
 
Although it is possible and valuable to run molecular dynamics 
simulations using quantum-chemistry algorithms, the costs of doing so would be 
prohibitively expensive for the vast majority of systems of interest given the 
computational resources typically available. It is, therefore, crucial to use 
approximations, and the classical one called Molecular mechanics (MM) is the 
principal of these used in biological macromolecular modelling[158]. 
 
Molecular mechanics treats atoms as spheres and bonds as springs. This 
is clearly a very coarse approximation, as it indirectly allows unrestricted small 
variations in energy, it defines bonds in a fixed manner, and it ignores electronic 
transitions therefore making it all but impossible to model chemical reactions. 
Nonetheless, a large number of computational chemistry calculations are 
concerned with the determination of bond lengths and angles. Molecular 
mechanics calculations can be remarkably accurate at this, and are thus highly 
regarded by the scientific community as a viable alternative to the intractable 
calculations that would be required in quantum descriptions of the computational 
structural biology[158]. 
 
A molecular dynamics simulation performs its calculations using what is 
called a molecular mechanics force field. This is essentially a description of the 
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force constants, equilibrium angles and lengths, and interactions between near 
neighbours’, including Coulombic and van der Waal’s interactions. Force fields 
also involve the definition of “atom types” since, for example, nitrogen in an 
amine group is expected to behave differently from one in a nitro group. This 
latter point draws attention to the validity of the force field when tackling a given 
problem. The accuracy that a researcher can expect depends on the molecules 
that were used to parameterize the force field. Therefore, no force field is 
universal, some being more appropriate for nucleic acids, others for globular 
proteins or for lipids, and so on[158]. 
 
The force field equation can be summarized by six main contributions to 
the total potential energy of the system, namely: bond stretching, bond bending 
(angle), dihedral torsions, out-of-plane torsions, electrostatic/Coulombic 
interactions (H bond), and other non-bonded interactions (2)[158, 159]. 
 𝐹!"!#$ = 𝐹!"#$ + 𝐹!"#$% + 𝐹!"!!"#$% + 𝐹!"#$%"&$ + 𝐹!  !"#$ + 𝐹!"!!!"#$%$   (2) 
 
Molecular dynamic simulations are performed with two types of 
simulations: an all-atom (AA) and coarse-grained (CG) simulations. The all-
atom molecular dynamics causes computational expense of explicitly 
representing every atom of the solute and solvent that limits all-atom molecular 
dynamic simulations to a timescale of tens of nanoseconds. To overcome this 
limitation, coarse grain molecular dynamic (CG-MD) force fields have been 
developed in which groups of atoms are represented by a single CG-MD bead. In 
particular, the Martini CG-MD force field that can run to a time scale of 
   Chapter 1: Introduction 
 54 
microseconds[160]. The Martini force field equation can be summarized by four 
main contributions to the total potential energy of the system, namely: bond 
stretching, bond angle, dihedral, Lennard-Jones/Coulombic interactions (3)[161]. 
 𝐹!"!#$ = 𝐹!"#$ + 𝐹!"#$% + 𝐹!"!!"#$% + 𝐹!" + 𝐹!"#$"%&'(   (3) 
 
The use of coarse-grained models in a variety of simulation techniques 
has proven to be a valuable tool to probe the time and length scales of systems 
beyond what is possible with traditional all-atom models[100]. Coarse-grained 
models, in which small group of atoms are treated as single particles, provide an 
approach to increasing the time scale and system dimensions of membrane 
simulations[162]. The Martini model is based on a four-to-one mapping, i.e., on 
average four heavy atoms are represented by a single interaction centre, with an 
exception for ring-like molecules (see Figure 1.6)[104]. For reasons of 
computational efficiency the mass of the CG beads is set to 72 amu 
(corresponding to four water molecules) for all beads, except for beads in ring 
structures, for which the mass is set to 45 amu[100]. Four major CG particle 
types are prominent: polar (P), mixed polar/aplolar (N), hydrophobic apolar (C), 
and charged (Q). Four subtypes for N and Q particle are found to allow more 
fine-tuning of the Lennard-Jones interactions reflecting the hydrogen bonding 
potentials. The four subtypes are: “0” for no hydrogen bonding capabilities 
present, “d” for groups acting as hydrogen bond donor, “a” for groups acting as 
hydrogen bond acceptor, and “da” for groups with both donor and acceptor 
options. These beads are split into four or five different levels giving a total of 20 
different beads For the interactions between the beads, 10 different interaction 
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levels are the beads used are at normal size (4:1 mapping) for the ring structures 
a smaller sized mapping (2/3:1 mapping) is used. All atoms except nearest 
neighbours interact through a Lennard-Jones potential. The nearest neighbours 
are connected by a weak harmonic spring, next nearest neighbours interact 
through a harmonic angle potential and the charged groups also interact through 
a short-range electrostatic potential[106, 161]. 
 
 
Figure 1.6 Martini force field water, sugar, protein and lipid beads representations. 
 
 
1.7.2 Homology Modelling 
Homology modeling is an in silico method, used for predicting the 
tertiary structure of an unknown amino acid target sequence from a close 
homologous crystallized template structure, in which the crystal structure has 
been determined experimentally, to produce an initial 3D structure of the target 
sequence as close to the native form of the protein[152]. 
CG#protein#bead#
representa/on#
CG#lipid#bead#
representa/on#
CG#sugar#bead#
representa/on#
CG#water#bead#
representa/on#
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In homology modelling, the two sequences are aligned together by either 
visual analysis or by using automatized algorithms, or a combination of the two, 
and then the produced alignment is fed into a specialized homology modelling 
software to construct the three-dimensional model of the unknown protein 
structure. 
 
1.8 Aims and outline of this study 
The aim of this thesis was to develop a method to investigate the helix-
helix dimerisation interface of two interacting GPCR protomers. The structure of 
the A2A homodimer is presently unknown. The variety of experimental methods 
with which to study oligomerisation of A2A, together with the availability of 
crystal structure data for this receptor, make it an ideal candidate with which to 
integrate experimental and computational methods to better understand the 
precise molecular nature of GPCR oligomers. 
 
The ability of the A2A receptor to form a homodimer at M1935.54 in TM5 
formed the starting point for this study. Experimentally, a BiFC system was 
developed to confirm previous findings of the TM5-TM5 interaction of the A2A 
receptor and to explore novel findings generated by the computational studies 
carried out in parallel. Computationally, a consistent, rapid and reproducible CG-
MD methodology was developed and used to study wild type and mutated TM 
helices of the A2AR receptor within lipid bilayers using the 3EML crystal 
structure as a template. The results from these in silico analyses were compared 
with the available experimental biophysical data and with the structural data for 
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the rhodopsin (1N3M), CXCR4 chemokine receptor (3ODU) and β1-Adrenergic 
receptor (4GPO) homodimers.  
 
The work presented in this thesis defines a novel computational method of 
ensemble-based coarse-grained classical molecular dynamics that can be used to 
systematically, reproducibly and reliably determine the specific points of 
interaction between GPCR dimers. This method will be of great utility in further 
understanding GPCR function and also has broad applicability to many different 
types of membrane proteins. 
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Chapter 2 
Materials & Methods 
2.1 Experimental Biology Techniques 
 
2.1.1 Cell Lines and Cell Culture Conditions 
The following sections describe the basic cell culture splitting and 
passaging techniques employed in this project. 
 
1321N1 (human astrocytoma) and HEK293T (human embryonic kidney) 
cells used were purchased from European Collection for Cell Cultures (ECACC). 
The cells were cultured in T75 tissue culture flasks using 50:50 v/v Dulbecco’s 
Modified Eagle’s Medium (DMEM/Sigma) supplemented with 50 mL of 10% 
fetal bovine serum (FBS/Sigma) and 5 mL of 10% L-glutamine (Sigma). The 
used medium was stored for a maximum length of six weeks at 4°C before 
replenishing the L-glutamine.  Cells were grown at 5% CO2 in a 37°C humidified 
tissue culture incubator (Heraeus) and were passaged, transfected and 
manipulated in a class II Laminar flow safety cabinet (Heraeus). 
 
2.1.2 Cell passaging and splitting 
The cells were split and passaged when they reached 100% confluence, 
forming a complete monolayer sheet that occupied the entire surface area of the 
flask. They were typically split and passed at 1:3, 1:10, or 1:20 with respect to 
the surface area of the flask depending on the speed of their growth cycle. The 
existing medium is aspirated and the cells washed with 10 mL of 1X Dulbecco’s 
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Phosphate-Buffered Saline (DPBS) (Sigma). To detach the cells from the growth 
surface they were incubated in 10 mL of DPBS-EDTA buffer, containing 5 mL 
of 0.5 mM EDTA.  The resuspended cells were then used to 1) reseed the flask 
or other flasks or 2) prepare ½ area plates-96 used for Lance cAMP assay. 
 
2.1.3 Cell counting 
To determine the volume of cell suspension needed to achieve the desired 
split, the density of resuspended cells was measured using the CASY® Cell 
Counter and Analyser System Model TT (INNOVATIS), a technology that 
performs “standardized cell counting methods, viability checks, aggregation 
correction, volumetric measurement with high measuring range dynamics.” A 
tailored setup, specifying the selected measuring parameters (used capillary, X 
axis or range of size distribution, sample volume and number of cycles), the 
evaluation parameters (dilution factor, Y axis, evaluation cursor, normalization 
cursor, % calculation, debris, aggregation correction, and mean volume) and 
output parameters (interface, page feed, print mode and graphic) was created and 
used throughout the project for all cell count measurements. After the cells were 
detached from the flask, approximately 1 mL of the suspension was transferred 
into a clean 1.5 mL Eppendorf test tube. 
 
In order to perform the cell count, a CASY®-cup was first filled with 10 
mL of CASY®ton buffer (Roche). 100 µL of the aliquoted cell suspension was 
then added to the buffer, following which the lid of the cup was secured and the 
cup was tilted a few times to mix the sample. The vial of diluted sample was 
placed on the platform below the measuring capillary, allowing an external 
electrode to be inserted into the sample. The START button was pressed to 
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initiate the measurement, which calculates the number of cells present in a given 
sample based on the resistance measurement of pulse area analysis. During the 
measurement, 400 µL of the sample was aspirated by a precision measuring 
capillary and slowly passed in a measuring pore, through which a low voltage 
was pulsed. The cells exhibited a size or dimension-dependent resistance to the 
voltage, whereby an isolated intact cell generated a higher resistance than a dead 
lysed cell. The resistance resulted from the nucleus membrane rather than the cell 
surface membrane, thus allowing the discrimination between living and dead 
cells. The density measurement was performed in triplicate. CASY® 
automatically operates the necessary steps, taking into account the dilution 
factor. A size distribution of the sample thus appears in the display, together with 
a complete numerical evaluation of the measurement data, specifying the number 
of viable cells in the measured sample in cells/mL and the percentage viability of 
the cells in the sample.  The density of resuspended cells was measured for each 
1) cell passage and 2) LANCE assay cell plate set-up in order to ensure that the 
same density of cells was plated across experiments for consistency and 
reproducibility purposes. 
 
2.1.3.1 Collection and freezing of cells 
Freezer cryotubes were created and labeled for the long-term storage of the 
newly created cell lines. The monolayer of cells in the T75 flask was first washed 
with DPBS then detached using 10 mL DPBS-EDTA buffer at room temperature 
for two minutes. The cell suspension was transferred to a clean 50 mL Falcon 
tube, centrifuged for 5 min at 1020 rcf, following which the tube was removed 
from the centrifuge and the supernatant was aspirated. A 10% DMSO-FBS 
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mixture was prepared by adding 9 mL of thawed FBS to 1 mL of DMSO 
(dimethyl sulfoxide). The cell pellet was resuspended in the DMSO-FBS 
mixture, and the obtained preparation was distributed into cryotubes (1 mL/tube). 
The ampoules were first stored in a -80°C freezer then transferred to liquid 
nitrogen. 
 
2.1.4 Cloning Techniques 
 The following sections depict the cloning techniques employed in this 
project, as well as the protocols used to generate the stable BiFC constructs and 
the mutated constructs. 
 
2.1.4.1 Primer Design 
Primers were designed (Table 2.1) for: a) the A2A receptor (Genbank 
accession number S46950) to allow the cloning of the receptor into the TOPO® 
TA cloning vector (LifeTechnologies) prior to the production of fusion 
constructs the biomolecular fluorescent protein complementation vectors were a 
gift from Chang-Deng Hu (pBiFC-VN173 (Addgene plasmid # 22010), pBiFC-
CC155 (Addgene plasmid # 22015); b) mutated primers were designed with each 
containing a single point mutation to substitute the methionine residues with 
alanine at the M177 and M193 positions in A2AR-TM5. The mutagenesis primers 
were designed to the specification of the QuikChange II XL Site-Directed 
Mutagenesis Kit (Agilent Technologies). All the primers were synthesized by 
eurofins genomics. 
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Type Sequence 5`        3` GC content Tm 
A) hA2AR Wildtype Primers 
Forward (37 bp) ATATGAATTCGTGGCCATGCCCATCATGGGCTCCTCG  54.1% 73.9 
Reverse C-terminus (31 bp) ATATCTCGAGGGACACTCCTGCTCCATCCTG  54.8% 70.8 
Reverse N-terminus (31 bp) ATATGTCGACGGACACTCCTGCTCCATCCTG  54.8% 70.8 
B) hA2AR Mutated Primers 
1) L19M20A (M193)  
Forward (39 bp) CTGGTGCCCCTGCTGTTCGCGCTGGGTGTCTATTTGCGG 64.1% >75 
Reverse (39 bp) CCGCAAATAGACACCCAGCGCGAACAGCAGGGGCACCAG 64.1% >75 
2) M4AV5 (M177) 
Forward (42bp) GTGGTCCCCATGAACTACGCGGTATACTTCAACTTCTTTGCC 50% 74.3 
Reverse (42 bp) GGCAAAGAAGTTGAAGTATACCGCGTAGTTCATGGGGACCAC  50% 74.3 
 
Table 2.1: The different primer sequences designed to amplify the A2AR 
receptor 
A) The hA2AR wildtype primer where designed to produce a wild type A2AR receptor, B) Primers 
designed to produce the single point mutation in the A2AR receptor at two different positions, 
M177A and M193A. 
 
2.1.4.2 Amplification of the Plasmid 
The A2AR sequence was amplified using the proofreading enzyme 
Accuzyme (Bioline), and the amplicon was cloned into the TOPO© vector 
(Invitrogen) followed by transformation into chemically competent TOP10F’ 
One Shot® cells (Invitrogen) and placed onto LB agar (Luria broth) plates 
containing 100 µg/mL ampicillin. 
 
2.1.4.3 Polymerase Chain Reaction (PCR) 
 PCR reactions were carried out to amplify the hA2AR DNA fragments. 25 
µL reactions were prepared reaction mixtures were prepared in flat cap PCR 
tubes and contained: 
1 µL forward primers 
1 µL reverse primers 
1 µL cDNA 
12.5 µL 2X AccuzymeTM 
9.5 µL of Nuclease-free water (Baxter) 
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The PCR reactions were conducted in the PCR Express Thermal Cycler 
(Thermo Hybaid) and performed in three stages. The first stage consisted of a 5 
minutes denaturation at 95°C for a single cycle. This was followed by a second 
stage comprising of 29 cycles of 1) 15 seconds of denaturation at 95°C, 2) 30 
seconds of primer annealing at 57°C and 3) 15 seconds of extension at 72°C. The 
final stage consisted of a 5 minutes extension at 72°C for one cycle. The finished 
reaction was held at 4°C. In order to check the presence of the amplified PCR 
products, agarose gel electrophoresis was performed.  
 
2.1.4.4 Cloning and Transformation 
The fresh amplified amplicon was transfected into TOPO© vector 
(Invitrogen) before ultimately transforming it into a chemically competent 
TOP10F’ One Shot® cells (Invitrogen). The reaction mixture contained: 
 
6 µL of the TOPO cloning reaction 
4 µL of fresh PCR product 
1 µL of salt solution (consisting of 200 mM NaCl and 10 mM 
MgCl2) 
1 µL of TOPO vector 
 
The reaction was incubated for 5 minutes at room temperature then 
placed on ice before transformating 2 µL of cloning mixture into competent 
TOP10F’ One Shot® Escherichia coli cells according to the manufacturers 
protocol and were plated on LB Agar plates containing Ampicillin 100 µg/mL 
overnight at 37°C. Only the white or light blue colonies were later selected for 
analysis. 
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2.1.4.5 Restriction Enzyme Digestion 
Restriction endonuclease (RE) digestion was carried out on the plasmids 
produced by the mini-prep GenEluteTM HP Plasmid Mini-prep Kits (Sigma) and 
pBiFC vectors, with approximately 1 unit of enzyme(s) per 50 µg of DNA, at 
37°C in water-bath (Grant) for one to one and a half hours. 
 
For the A2AR PCR product digestion was prepared containing: 
3 µL plasmid DNA 
1 µL 10X Buffer H (Promega) 
0.5 µL EcoRI (10 u/µL, Promega) 
0.5 µL SalI or XholI (10 u/µL, Promega) 
5 µL of distilled water (Baxter) 
 
For the pBiCF vectors digestion was prepared containing: 
10 µg pBiFC-(VN173 or CC155) vector 
20 µL 10X Buffer H (Promega) 
5 µL EcoRI (10 u/µL, Promega) 
5 µL SalI or XholI (each at 10 u/µL, Promega) 
The volume was adjusted with distilled water (Baxter) 
 
2.1.4.6 DNA Ligation 
The ligation process was prepared in 0.2 mL flat cap PCR, a molar ratio 
of 1:3 pBiFC vectors to DNA insertion. The maximum plasmid vector 
concentration used was 50 ng per reaction. 
 
For ligation process 20 µL mixture were prepared and contained: 
1 µL of the T4 DNA Ligase (NewEnglandBiolabs-NEB) 
2 µL of 10X Ligase buffer (NEB) 
2-5 µL of DNA insert 
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The volume was adjusted with distilled water and the reaction was either 
incubated at room temperature for one hour or at 10°C overnight. Following 
ligation, the reaction mixtures were transformed using One Shot® TOP10F` 
cells, according to the manufactures instructions and were plated on LB Agar 
plates containing Ampicillin 100 µg/mL. 
 
2.1.5 Gel Electrophoresis and Purification 
To view the PCR products, after every amplification/restriction enzyme 
digestion, a 1% agarose gel in 1X TAE buffer was prepared and the gel was pre-
stained with ethidium bromide (10 mg/mL) (Fluka). DNA samples were prepared 
by adding 2 µL of 5X Loading Buffer (Bioline) to 5 µL of PCR reaction. The gel 
was run in 1X TAE buffer for 30 minutes at 120 V. The Invitrogen 1 Kb Plus 
DNA ladder (10 µL) was used as standard marker. DNA bands were visualized 
under a UV-Transiluminator (Syngene). 
 
The desired A2AR DNA fragment (~1100 bp) and pBiFC vector 
fragments (~4100-5100 bp) were excised from gel by High Pure PCR Product 
Purification kit (Roche) according to the manufacturers protocol. 
 
2.1.6 Transfection of Cells with Plasmids 
Generation of the transient 1321N1 cells was undertaken using the 
LipofectamineTM 2000 (Invitrogen) method, a patented formulation with the 
highest transfection efficiency for many eukaryotic cell types with circular 
nucleic acids. 
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The exponentially growing untransfected 1321N1 cells were grown in T75 
flask until they were 90-95% confluent. The cells were then split and transferred 
into a clean 50 mL Falcon tube. The densities were then counted and cell 
suspensions of 40,000 to 80,000 cells/cm2 cells in DMEM were each plated in 
either 96- or 6-well plates. The cells were transfected with 0.2 µg of the A2A-
pBiFC-VN173/CC155 plasmids, transfection protocol was carried-out according 
to the manufactures’ procedure. The cells were incubated in 5% CO2 humidified 
tissue culture incubator for 18-48 hours prior to testing expression. 
 
2.1.7 Plasmid DNA Preparation 
The screening for the desired recombinant plasmid constructs was 
conducted through the GenEluteTM HP Plasmid Mini-prep Kits (Sigma). A single 
colony was chosen and picked from the LB agar plates and inoculated in 2 mL 
LB broth containing 100 µg/mL Ampicillin. The culture was grown in 14 mL 
Falcon 2059 Polypropylene round-bottom tube (Becton Dickinson) at 37°C 
shaker incubator at 200 rpm overnight. 
 
Following the mini-prep screening, large-scale transfection grade plasmid 
DNA of the remaining culture was isolated using QIAGEN Plasmid Maxi KitTM 
according to the manufactures’ instructions. 
 
2.1.8 Quantification of DNA 
The extracted DNA was quantified using NanoDropTM 2000 (Thermo-
scientific) measurements, which can determine the absorbance of a given sample 
at different wavelengths. The DNA concentration was measured in ng/µL and the 
OD260/280 ratio of the analysed sample was determined. This ratio indicates the 
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purity of DNA, whereby a ratio of approximately 1.8 is accepted as pure for 
DNA. 
 
2.1.8.1 LANCE® Ultra cAMP assay 
The LANCE® Ultra cAMP assay (PerkinElmer) is a second generation 
homogeneous time-resolved fluorescence resonance energy transfer (TR-FRET) 
immunoassay designed to measure cAMP produced upon modulation of adenylyl 
cyclase activity by any Gs- or Gi-coupled GPCRs in the cellular membrane 
samples. The assay principle is based on the competition between the europium 
(Eu) chelate-labeled cAMP tracer and sample cAMP for binding sites on cAMP-
specific monoclonal antibodies labeled with the ULightTM dye (Figure 2.1). 
When antibodies are bound to the Eu-labeled cAMP tracer, light pulse at 320 or 
340 nm excites the Eu chelate molecule of the tracer. The energy emitted by the 
excited Eu chelate is transferred by FRET to ULight molecules on the antibodies, 
which in turn emit light at 665 nm. Residual energy from the Eu chelate will 
produce light at 615 nm. In the absence of free cAMP, maximal TR-FRET signal 
is achieved (Figure 2.1, left panel). Free cAMP produced by stimulated cells 
competes with the Eu-cAMP tracer for the binding to the ULight-mAb, causing a 
decrease in TR-FRET signal. The intensity of the signal measured at 665 nm is 
inversely proportional to the cAMP concentration in the sample. 
 
This technique provides high sensitivity and signal stability, constitutes a 
standard approach for the pharmacological characterization and determination of 
relative potencies of ligands at receptors, thus allowing a quantification of 
agonist effects. 
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In the absence of free cAMP     In the presence of free cAMP  
 
Figure 2.1 The Lance® Ultra cAMP assay[163].  
 
 
2.1.8.2 The LANCE® Ultra assay procedure 
The standard assay procedure is conducted in two steps. In the first step, 
cells or cAMP standard in suspension are stimulated for 30 min with the selected 
compound(s). Following stimulation, cellular cAMP is detected by the 
successive additions of Eu-cAMP tracer and ULight-anti-cAMP prepared in the 
cAMP Detection buffer provided with the kit. The TR-FRET signal at 665 nm is 
measured by SpectraMax i3 (Molecular Devices). cAMP standard curves are 
preformed to determine the assay sensitivity and dynamic range provided by 
each cAMP. 
 
4X serial dilutions were prepared for the cAMP, Eu-cAMP tracer and 
ULight-anti-cAMP in Stimulation buffer pH 7.4. The 4X cAMP serial dilutions 
were prepared in half log units from 10-6-10-11 M with a starting concentration of 
50 µM cAMP standard supplied in the kit. The 4X Eu-cAMP tracer working 
solution was prepared by making a 1/50 dilution of the Eu-cAMP tracer stock 
solution in cAMP Detection buffer supplied in the kit, where 980 µL of cAMP 
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Detection buffer was added to 20 µL of the Eu-cAMP tracer aliquot stock 
solution and mixed gently. The 4X ULight-anti-cAMP working solution was 
prepared by making a 1/150 dilution of the ULight-anti-cAMP stock solution in 
cAMP Detection buffer, where 6.7 µL of the ULight-anti-cAMP aliquot stock 
solution was diluted with 998.3 µL of cAMP Detection buffer and mixed gently. 
 
The Stimulation buffer, 15 mL pH 7.4, was prepared in 50 mL Falcon 
tube and contained: 
14 mL of 1X HBSS (Invitrogen)  
75 µL of 1M HEPES pH 7.2-7.5 (Invitrogen)  
150 µL 100 µM RO-201724 
200 µlL of 7.5% BSA Stabilizer (included in the kit)  
The pH was adjust with 0.1 N NaOH and the volume was 
completed to 15 mL with 1X HBSS 
 
The LANCE® Ultra assay was prepared in ½ AreaPlate-96 white plate. 
A final volume of 40 µL was prepared and contained: 
10 µL of the cells or cAMP 
10 µL of compounds or Stimulation buffer 
10 µL of Eu-cAMP tracer 
10 µL ULight-anti-cAMP 
 
The reaction had two incubation steps. The cells or cAMP with 
compounds or stimulation buffer were incubated for 30 minutes at room 
temperature. Subsequently, after addition of the Eu-cAMP tracer and the ULight-
anti-cAMP the mixture was sealed with microplate seal and incubated at room 
temperature for one hour. The plate was then read on SpectraMax i3. White 
plates were used as the black plates reduce the signal. 
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2.1.8.3 Cell density optimization 
The first step in the assay was to identify the optimal cell density by 
performing a forskolin and cell density cross-titration experiments. A replica of 
three experiments was preformed for this. Cells were grown in T75 flask until 
they reach 100% confluent, washed in DPBS and lifted in 10 mL DPBS-EDTA 
as previously described. The detached cells were then transferred to 50 mL 
Falcon tube and counted to determine the volume of cell suspension required to 
generate a 10x107 cells/mL dilution. Sequentially, 1 mL of the obtained 10x107 
dilution was dispensed into another tube and centrifuged for 5 minutes at 1020 
rcf, and the DPBS-EDTA buffer was aspirated. The cells were re-suspended in 
Stimulation buffer according to the cell density need for plating, approximately 
10x105 cells/well and 10 µL of the mixture was seeded onto appropriate well of a 
½ AreaPlate-96 followed by addition of the selected compounds. 
 
2.1.8.4 Running the LANCE® Ultra Assay 
The cAMP measurement assays were conducted using the SpectraMax® 
i3 (Microplate Plate Reader) (Molecular Devices). This technology uses an 
integrated optical system enabling top and bottom reads for 6 - 384 well 
microplates with three broad detection modes: luminescence, absorbance, and 
fluorescence with a possibility to upgrade to additional applications and 
detection modes such as cartridges for Time-Resolved Fluorescence. We have 
used the Cisbio HTRF cartridge for Time-Resolved Fluorescence (0200-7011). 
 
 After the one-hour incubation at room temperature the microplate seal was 
removed and the plate was loaded into the SpectraMax i3. First, the plate type 
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was selected (½ AreaPlate-96) and then an optimization run was conducted to get 
the recommended height read of the samples in the plate, for a 40 µL sample the 
recommended read height was usually between 5.38 mm to 5.56 mm. The 
SpectraMax i3 system was programmed to utilize a Xenon flash lamp. The 
excitation filter was set at 340 nm with an excitation time of 0.05 ms and 20 
pules. The fluorescent signals are emitted from the Eu chelate following 
excitation and passed through an emission filter was a wavelength of 616 nm, the 
ULight FRET emission signal was passed through the 665 nm filter. The 
emission measurement delay was set to 0.03 ms after excitation. The integration 
time was set to 0.5 ms. These emission were passed through cooled 
Photomultiplier tubes (PMT) channel with two dichroic filters located on top of 
the cell plate, allowing fluorescent/FRET signals to be collected. 
 
 The recorded data was saved on the SoftMax Pro software for statistical 
analysis. They were then subjected to further analysis using GraphPad Prism. 
 
2.1.8.5 Cisbio HTRF SpectraMax® Detection Cartridge 
The HTRF technology combines standard FRET technology with time-
resolved measurement of fluorescence that eliminates the short-lived background 
fluorescence. HTRF acceptors emit long-lived fluorescence when engaged in a 
FRET process this will compensate for compound interference and sample 
quenching and also minimizes background fluorescence detection. Therefore, the 
long-lived emissions signify energy transfer due to the proximity of the labeled 
biomolecules. The FRET technology relies on the physics of molecular 
proximity, when the distance between the donor and the acceptor is short 
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enough. A FRET system is characterized by the Förster's radius (R0) distance at 
which FRET efficiency is 50%. The HTRF R0 lies between 50 and 90 Å, 
depending on the acceptor used. The cartridge uses a Xenon flash light source, 
with an excitation filter of 320 or 340 nm and the emission 0 EM1 616/10 nm to 
EM2 665/10 nm.  The HTRF cartridge used measures the emissions of the Eu-
cAMP tracer and the transferred energy from Eu chelate to the ULight-anti-
cAMP simultaneously, at the 616 nm and 665 nm respectively. 
 
2.1.8.6 Data Analysis 
 The statistical and quantitative analysis of data was conducted using 
SoftMax Pro 6.4 and GraphPad Prism®. SoftMax Pro was used for primary 
calculations based on TR-FRET signal obtained from SpectraMax. Two signals 
were obtained at 665 nm (Ulight acceptor channel) and 616 nm (Eu chelate 
donor channel). The TR-FRET signal at 665 nm was used directly for data 
analysis of: 1) cAMP standard curves, Figure 2.2 shows counts at 665 nm 
obtained in cAMP standard curves that allow interpolating the amount of cAMP 
produced in stimulated cells; 2) determination of optimal cell density; 3) for 
agonist and antagonist characterization. The signal at 616 nm is used to identify 
dispensing malfunctions and some compounds artifacts that can lead to signal 
decrease. To overcome this a quench correction calculation was performed using 
a blank-corrected normalized ratio, the following equation in SoftMax was 
applied: 
 
F665,CS = [(F665,S – F665,BL) x F616,MAX] / F616,S 
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 Where the corrected signal (F665,CS) is produced through determining the 
blank value (F665,BL) by measuring the background signal at 665 nm of buffer 
containing wells. The (F665,S) and (F616,S) signals were determined from sample 
wells containing the assay components and test compounds. The (F616,MAX) was 
obtained from wells with no cAMP. 
 
The Prism® software was employed for the analysis of data processed 
using SoftMax Pro, through curve fitting through non-linear regression. Each 
represented data set consisted of three or more replicates (n=3) for each 
concentration level. 
 
 
Figure 2.2 cAMP standard curve. 
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2.2 Computational Biology Systems 
 The following sections describe the modelling, simulation parameters 
employed in adenosine A2A receptor, rhodopsin, CXCR4 and β1AR 
transmembranes simulations, as well as, how the CG-MD simulations were 
analysed. The aim was to develop a consistent, rapid, reproducible CG-MD 
methodology for the study of interacting helices. This method will involve 
placing two GPCR transmembrane helices in a membrane and running ensemble 
simulations comprised of multiple replicas, each, hoping to identify interactions 
between the helices. In these simulations, distance will be used as a means of 
identifying two different types of interactions: interactions between helices and 
interactions between amino acid residues on each helix. For the successful 
interaction of both types of interaction, it will be necessary to specify the number 
of replicas (independent simulations identical other than for the initial velocity 
seeds assigned to the particles) and the run time needed to achieve converged 
results and see how well they reproduce experimental results. The number of 
replicas must be sufficient to achieve a reproducible result as evidenced by a 
sufficiently small error estimate. 
 
From Table 1.4, it can be seen that the longest total simulation time for 
atomistic MD is 0.1 μs and for CG simulations is 200 μs. The formation of a 
long-lasting helix dimer was identified within a few hundred nanoseconds in CG-
MD studies of Glycophorin A, a non-GPCR model for studying TM membrane 
protein structure[86]. The number of replicas performed in these different studies 
varies tremendously, but is never greater than 10. Excellent agreement has been 
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obtained between computed binding free energies and experimental data when 
ensembles of 50 replicas are used[164]. 500 ns was selected for the run time and 
50 replicas as starting parameters for these studies. These calculations were run 
on Legion and Grace, two high-performance Research Computing cluster at UCL 
(for details of the machines used can be found at 
https://wiki.rc.ucl.ac.uk/wiki/RC_Systems#Legion_technical_specs  
and https://wiki.rc.ucl.ac.uk/wiki/RC_Systems#Grace_technical_specs). Our 
preliminary tests showed that CG-simulations (1 ensemble) run on Legion for 
500 ns completed within approximately 150 hours. CG-simulations (1 ensemble) 
run on Grace for 500 ns completed within approximately 72 hours. 
 
2.2.1 CG Simulations 
All CG-MD simulations were performed in GROMACS (version 4.6.4) 
(www.gromacs.org). The temperature was equilibrated for all three groups: 
protein, lipid bilayer, and solvent (water) with ions to remove center of mass 
motion relative to the bilayer and protein. The thermalisation run was carried out 
for 100 ps. The simulation was then run at 310 K (the mammalian physiological 
temperature), which is below the phase transition temperature of pure DPPC 
(315 K). The system output of the temperature was evaluated to make sure that it 
stabilized at the required temperature (310 K) before continuing until pressure 
equilibration was attained. An ensemble of 50 replicas for each simulation box 
(see Tables 2.2 and 2.3) was performed. Each simulation was run for 500 ns. 
CG-atom velocities were drawn from a Maxwell-Boltzmann distribution at 
T=310 K, but all other variables were kept constant, therefore standard deviation 
was used to compare differences in mean distance outputs. Each simulation was 
run independently, with the initial configuration differing only by the starting 
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velocity; they were performed under constant temperature, pressure, and particle 
number using the Martini 2.2 force field[165]. The temperature of the protein 
and the lipid were coupled using the velocity-rescaling (modified Berendsen) 
thermostat at 310 K (human physiological body temperature), with a coupling 
constant of Tt = 1 ps. The system pressure was semi-isotropic using the 
Berendsen algorithm at 1 bar, with a coupling constant of Tp = 1 ps and a 
compressibility of 1x10-4  bar-1. A time step integration of 30 fs was chosen and 
the coordinates were saved every 10000 subsequent steps for further analysis. 
The electrostatic interactions were shifted to zero between 0 to 1.2 nm. The 
Lennard-Jones (LJ) potential was shifted to zero between 0.9 to 1.2 nm to reduce 
the cutoff noise. The neighbour list for pairwise non-bonded interactions was 
determined by the Verlet cutoff scheme at 1.4 nm and updated every 10 steps. 
 
Simulations for the A2AR receptor were carried out as follows: 1) 
wildtype TM5 helices; 2) mutated TM5 helices at M177A helices found in the 
other PxxxM conserved motif in all of the adenosine receptors; 3) mutated TM5 
helices at M193A[64] helices; 4) mutated TM5 helices at M193 helices to 
isoleucine (M193I) because PxxxI is the conserved motif found in the P2Y 
receptors located in same position as the PxxxM motif in the P1 receptors; 5) 
mutated TM5 helices at Y197A and Y197F; 6) simulations of pairwise 
combinations of all the homo/heterologous possible pairs of the A2AR TM 
helices (TM1, TM2, TM3, TM4, TM5, TM6, and TM7); 7) mutated TM1 helix 
at E13A with TM2 found to be a strong interacting pair from pairwise 
simulation. The choice of mutating residues to alanine was motivated by 
standard biochemical techniques (such as alanine scanning mutagenesis) for 
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assessing side-chain function. The DPPC lipid bilayer used in system resembles 
a biological membrane designed for drug delivery[166]. Sequences used in all 
the simulations are found in Table 2.2. 
 
Simulations for the other GPCRs were carried out as follows: for 
rhodopsin 1) TM1-TM2 helices, 2) TM4-TM5 helices; in CXCR4 1) TM5-TM6 
helices, 2) TM5-TM5 helices and in β1AR 1) TM1-TM2 helices, 2) TM4-TM5 
helices and 3) TM1-TM1 helices. Sequences used in all the simulations are found 
in Table 2.3. 
 
A2AR α-Helices Sequences 
TM1 VYITVELAIAVLAILGN1.50(24)VLVCWAV 
TM1-E6A VYITVALAIAVLAILGN1.50(24)VLVCWAV 
TM2 FVVSLAAAD2.50(52)IAVGVLAIPFAITI 
TM3 L(78)FIACFVLVLTQSSIFSLLAIAI3.49(100) 
TM4 KGIIAICW4.50(129)VLSFAIGLTPMLG 
TM5-Wild-type MNYMVYFNFFACVLVP5.50(189)LLLMLGVYLRI 
TM5-M177A MNYAVYFNFFACVLVP5.50(189)LLLMLGVYLRI 
TM5-M193A MNYMVYFNFFACVLVP5.50(189)LLLALGVYLRI 
TM5-M193I MNYMVYFNFFACVLVP5.50(189)LLLILGVYLRI 
TM5-Y197A MNYMVYFNFFACVLVP5.50(189)LLLMLGVALRI 
TM5-Y197F MNYMVYFNFFACVLVP5.50(189)LLLMLGVFLRI 
TM6 LAIIVGLFALCWLP6.50(248)LHIINCFTFF 
TM7 WLMYLAIVLSHTNSVVNP7.50(285)FIYAYRI 
 
Table 2.2 Sequences of the A2AR helices used in simulations 
 
A2AR TM5 sequence and its mutated residues suggested to play a key role in the 
dimerisation of the A2AR TM helix are in bold; the mutated residues are underlined and 
written in italic (blue). The conserved amino acid numbered through the Ballesteros 
and Weinstein system of each individual transmembrane is shown in red. 
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Receptor Helices Sequencesa 
Rhodopsin TM1 QFSMLAAYMFLLIMLGFPIN1.50(55)FLTLYVTVQ 
TM2 NYILLNLAVAD2.50(83)LFMVFGGFTTTLYTSLH 
TM4 ENHAIMGVAFTW4.50(161)VMALACAAPPL 
TM5 NESFVIYMFVVHFIIP5.50(215)LIVIFFCYGQ 
CXCR4 TM5 VVVFQFQHIMVGLILP5.50(211)GIVIL 
TM6 VILILAFFACWLP6.50(254)YYIGISI β1AR TM1 QWEAGMSLLMALVVLLIVAGN1.50(59)VLVIAAIG 
TM2 NLFITSLACAD2.50(87)LVMGLLVVPFGATLVV 
TM4 ARAKVIICTVW4.50(166)AISALVSFLPIMM 
TM5 AYAIASSIISFYIP5.50(219)LLIMIFVYLRVY 
 
Table 2.3 Sequences of the rhodopsin, CXCR4 and β1AR receptor helices 
used in ensemble simulation sets 
 
a The conserved amino acid for each TM helix is shown in red and is numbered using both the 
Ballesteros and Weinstein nomenclature (superscript) and by residue number. 
 
 
2.2.2 Construction of TM Helices and Preparation of the Simulation Box  
Initial simulations were performed using TM5 of the human A2A 
adenosine receptor, which has been shown experimentally to form a 
homodimer[147]. Amino acid positions have been described using amino acid 
number in conjunction with the Ballasteros Weinstein nomenclature[167] (in 
superscript).  The A2A TM helices sequences shown in Table 2.2, were generated 
using MODELLER 9.12 following the procedure detailed[168, 169], using the 
crystal structure of the A2A receptor (PDB accession number 3EML; GI: 
209447557)[137]. The atomistic helices were subsequently converted into CG 
models using the “martinize” Python script (see Figure 2.3)[105]. A simulation 
box of dimensions 8 nm x 8 nm x 8 nm was constructed containing two wild-
type TM5 helices (Figure 2.4). The helices were placed 4 nm apart and aligned in 
a parallel orientation mimicking the natural positioning of the helix in the 
membrane (see Figure 2.4a), with their long axes parallel to the z-axis of the box 
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(see Figure 2.4b). The TM helices were separated by 4 nm at the beginning of the 
simulation to rule out any initial inter-helix interactions. Water and lipids were 
then added. Approximately ~190 molecules of the 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) lipid bilayer and additional water molecules (~2660-
2690) were added in coarse-grained form in a 3-dimensional cuboid box with 
periodic boundary conditions using the “insane” Python script[170]. To 
neutralise the net charge on the protein, water molecules were replaced by 
counterions (either Na+ or Cl-, as appropriate, depending on the amino acid 
composition of the helices). The rhodopsin, CXCR4 and β1AR TM helices 
sequences shown in Table 2.3, and were constructed as described above for the 
A2A receptor. 
 
 
Figure 2.3 Mapping between the chemical structure at the atomistic level (AA) with the 
coarse-grained (CG) Martini model[100] 
 
The CG beads are shown as transparent vdW spheres for DPPC lipid bilayer, a protein fragment, 
water and some amino acids. 
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2.2.3 Dimer Analysis 
Interhelix distance matrices were calculated for the helix-helix dimer 
formation and contact maps used to identify specific interactions between 
residues were generated using the GROMACS tool g_mdmat. The individual 
helix-helix contacts from each replica were examined by calculating the resulting 
inter-helix distance matrices from the initial simulation starting distance of 4 nm 
(40Å) to assess the reproducibility, number of replicas and run time needed to 
achieve convergence through a locally written code. In those runs where 
dimerisation was observed, the trajectories were combined and examined in 
greater depth by calculating the averaged inter-helix distance matrices with three 
different truncation distances, 15Å, 12Å and 10Å, to determine the dimerisation 
properties between the helices. A cutoff distance of 10Å was then applied to 
identify residues involved in helix-helix interactions. To investigate the influence 
of the number of replica simulations on the reliability of our results, we 
calculated mean interaction distances for ensembles of varying size. For 
evaluations of run length, mean distance output for the entire ensemble was 
calculated at 100 ns increments. 
 
Representative atomistic structures of the different CG dimers were 
generated through use of the “backward” Python script[171] and the g_cluster 
tool in GROMACS using the gromos algorithm at a cutoff of 2.5 nm[172]. 
Visualization was performed using VMD[173]. Approximate distances between 
the atomistic residues in interacting helices were measured using Jmol. Pairwise 
combinations used in the analyses were obtained from a matrix of the number of 
residues in helix 1 multiplied by the number of residues in helix 2. In the A2A 
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receptor, there are 729 possible pair combinations between the two 27 residue 
long TM5 helices, for example, combination 552 specifies the combination of 
residue 23 (helix 1) with residue 24 (helix 2), representing the V1965.57-Y1975.58 
interaction. 
 
Given the A2AR seven TM helices, there are 28 possible pairs in total 
where 21 would be heterologous pairs and seven possibly homologous pairs. 
Also there are three pairs from mutated TM5 helices interactions. All of these 
possible self-interactions were examined in silico.  The terms “stable dimer” and 
“dimerisation” to refer to interactions between helices. A 10Å truncation cutoff 
(backbone to backbone) has been set for dimerisation, as it has been shown 
experimentally that a unique FRET signal is generated when two labeled 
peptides are located within 10Å of each other and form an excited stated 
dimer[174]. The term “specific interactions” will be used to refer to interactions 
between amino acid side chains on the dimerised helices.  Specific interactions 
will be identified from contact matrices (heat maps). Although a 12Å truncation 
cutoff had previously been used to analyse these[175], we will set our interaction 
cutoff to 10Å, since the existence of hydrogen bond (Cα-H......O) contacts as a 
function of the inter-helical axial distance is between 6 and 12Å. Side-chain to 
side-chain distances consistent with this are used to identify specific interactions, 
with distances of 5-7Å reflecting stronger interactions. Not all pairs examined 
showed a favor to the homo- or hetero- dimer formation. 
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Figure 2.4 A simulation box of two wild-type TM5 helices 
a) A representation of the A2A receptor structure shows the direction of the TM helices in the 
lipid bilayer. b) A representation of the positioning of the TM in a simulation box before the 
addition of lipid and the water. 
 
 
2.2.4 Visualisation and Data Analysis 
All the simulations were extensively viewed with the graphical viewing 
package VMD[173] during all the steps of the simulation. The results obtained 
after MD runs were plotted with Xmgrace[176]. Representative structures of the 
interacting helices were generated using g_cluster tool in Gromacs, with the 
gromos algorithm[172] to cluster on RMSD with a cutoff of 2.5 nm. 
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Chapter 3 
Development of an integrated 
experimental-computational approach 
for the characterisation of GPCR 
dimers 
 
 
3.1 Introduction 
As described in Chapter 1, GPCRs exist in various oligomeric forms that 
have shown to be of functional relevance. A means of accurately identifying the 
specific points of interaction between GPCR dimers will provide valuable 
information about receptor function and is essential for the design of receptor 
ligands against specific oligomeric receptor targets. A wide variety of different 
approaches have been used to characterise GPCR dimers. Biophysical methods 
have been used to identify protein-protein interactions, with site-directed 
mutagenesis used to identify key amino acid residues involved in dimer 
formation. These experiments are able to be replicated multiple times, producing 
reproducible results that identify interactions between two protein domains and 
provide some clue to the amino acids involved, but do not provide detailed 
molecular information about the interaction interface. The computational 
modeling of mammalian GPCR dimers, shown in Table 1.4, can provide detailed 
molecular information, but these have typically been single simulations and not 
multiple replicas performed according to a standard protocol; the reliability and 
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accuracy of the molecular information they provide remains to be demonstrably 
proven. There is, therefore, a need for a methodology that integrates both 
experimental and computational data in the analysis of GPCR dimerisation, in 
order to provide accurate information about the molecular nature of the dimer 
interface between two interacting GPCRs. As previously explained, the A2A 
receptor has been shown experimentally to dimerise at M193 of TM5 and a 
number of A2A crystal structures have been obtained, making this an ideal model 
with which to develop an integrated experimental-computational approach to the 
study of GPCR dimers. 
 
This chapter endeavours first to establish an experimental system within 
which to evaluate the protein-protein interactions between two GPCR monomers 
at both the biochemical and the functional level.  This system will be developed 
using the experimental data that have been obtained for the A2A receptor TM5 
dimerisation interface. A2A dimerisation will be detected experimentally, through 
biochemical assays such as the BiFC technique, and through functional assays, 
such as the measurement of cAMP production, which is the primary signaling 
pathway of Gs-coupled GPCRs, including the A2A receptor. This chapter 
subsequently aims to develop a computational method for obtaining results in 
silico that match the experimentally-obtained data for the self-association of the 
TM5 helices of the A2A receptor. TM2 will be used as a negative control, as it 
was unable to form a homodimer under the same experimental conditions[64]. 
The computational method of choice is ensemble-based molecular dynamics 
simulations. This method has been chosen because neighboring trajectories 
diverge exponentially rapidly and only probabilistic descriptions are meaningful. 
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For these intrinsic reasons, collections of trajectories differing only in their initial 
conditions, known as ensembles, are the best means of studying the properties of 
such systems. Each individual system in the ensemble is referred to as a replica.  
 
The development of an integrated experimental-computational approach 
to the characterization of GPCR dimers will be carried out in two sequential 
steps. First, the 85dimerisation of the full-length A2A receptor will be structurally 
verified using the BiFC technique by constructing wild-type and M193A-
mutated receptors and transfecting these into HEK293T cells. Signalling will be 
characterized by measuring cAMP levels using the Lance Ultra® technique in 
recombinant HEK293T cells transiently expressing these BiFC constructs. 
Second, the A2A receptor 85 dimerisation interface will be investigated 
computationally through CG-MD simulations of wild-type and mutated TM5 in 
DPPC lipid bilayer. The minimum number of replicas in an ensemble and the 
minimum run time for each replica that is required to obtain results that converge 
with experimentally-obtained data will be determined. 
 
3.2 Creation and functional testing of the A2A-BiFC Constructs 
The co-immunoprecipitation human A2AR construct (GenBank accession 
number S46950) was generated for the wild-type A2AR. The hA2AR cDNA was 
then amplified using one forward and two reverse primers to accommodate the 
later insertion into the two BiFC plasmids minus stop codon, 1) pBiFC-CC155 
and 2) pBiFC-VN173. The resulting product bearing the 5` and 3` additions was 
1263 bp long. This fragment was assembled through ligation into a TOPO® TA 
cloning vector that possess an Ampicillin gene. The ligation reaction product was 
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transfected into TOP10F` One Shot® chemically competent E.coli, following 
which the transformation was plated on Ampicillin selective agar plates. A 
small-scale isolation of plasmid DNA (miniprep) was performed to screen for the 
ligation process products that represents the desired recombinant plasmid 
constructs and a restriction enzyme digestion was conducted to test for the 
successful insertion of hA2AR in the TOPO vector. The purified DNA was cut 
with EcoRI, SalI, and XhoI, yielding two fragments of the correct size 
corresponding to the TOPO vector (3900 bp) and hA2AR (1263 bp), respectively. 
Large-scale isolation of plasmid DNA was subsequently carried out using 
QIAGEN to hA2AR, following which the purified DNA was digested using 
previously mentioned restriction enzymes. 
 
3.3 Creation of the A2A-BiFC constructs 
A fluorescent A2AR constructs were created using the co-
immunoprecipitates cDNA described previously was tagged with the two 
fluorescent partners, Venus and Cerulean. cDNA was cloned into Venus (pBiFC-
CC155) between the EcoR1 and XholI sites and into Cerulean (pBiFC-VN173) 
between the EcoR1 and SalI sites (shown in Figure 3.1). The cDNAs encoding 
the A2AR were tagged at their N-terminal domain with either an HA or a FLAG 
tag immediately preceded by a consensus Kozak sequence to facilitate 
translation. The stop codon was removed from the GPCR coding sequences so 
that all downstream FP sequences could be fused in-frame. A linker sequence at 
the 3`-end of the GPCR was employed to keep the sequence in-frame. 
Immediately downstream from the linker, the cDNA encoding partial sequences 
of the relevant FP, either the EYFP N-terminal fragment comprised of amino 
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acids residues 155-239 (C155) of Venous, or the ECFP C-terminal fragments 
comprised of residues 1-172 (N173) of Cerulean, were fused in-frame. The 
resulting constructs are chimeric fusions. The cloning steps used to generate the 
chimeric BiFC constructs are found in Figure 3.2. 
 
Subsequently, two mutated hA2AR-BiFC constructs the 1) mutated A2AR-
M177A and the 2) mutated A2AR-M193A were generated through amplification 
of hA2AR-BiFC constructs using a set of forward and reverse primers containing 
the mutated sequences (primers length ~39-42 bp) using the QuikChange II XL 
Site-Directed Mutagenesis Kit. 
 
 
 
 
Figure 3.1 Schematic representation of the BiFC-CC155 constructed design 
The GPCR were excised from TOPO-PCR vector and inserted in the pBiFC-VN173 FP vector. 
The GPCR sequence is cloned between EcoRI and XhoI sites and is fused to an epitope 
HA/FLAG at the 5` end of the receptor sequence, it lacks a stop codon. The FP sequence is 
cloned between KpnI and NotI sites. The linker sequence encodes a peptide consisting of 27 
amino acids in length that is a part of the polylinker of the mammalian vector. 
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Figure 3.2 Agarose gel analysis of the cDNA constructs building steps to prepared for the 
BiFC assay 
The size of the DNA Ladder is on the left. A) The amplified A2AR cDNA fragments prepared for 
the insertion into the TOPO10F’ vector. From left-to-right: DNA Ladder; HA-A2AR cDNA; 
FLAG-A2AR cDNA. B) The A2AR cDNA fragments were excised from the TOPO TOP10F’ 
vector for insertion into pBiFC vectors (EcoRI and SalI/XhoI). From left-to-right: DNA Ladder; 
pBiFC-VN173 vector; pBiFC-CC155 vector; blue control colony; HA-A2AR; FLAG-A2AR 
fragments. C) Purified digested fragments, two different concentrations of the A2AR cDNA and 
pBiFC-vectors were placed. From left-to-right: DNA Ladder; pBiFC-VN173 vector; pBiFC-
CC155 vector; HA-A2AR; FLAG-A2AR fragments. D) The ligated A2AR cDNA into the pBiFC-
vectors. From left-to-right: DNA Ladder; HA-A2AR with pBiFC-VN173 vector (ECFP 1-172) 
(EcoRI and SalI); FLAG-A2AR with pBiFC-CC155 vector (EYFP 155-239) (EcoRI and XhoI). 
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3.4 Analyses of A2A-BiFC constructs 
The generated BiFC constructs, the pBiFC-VN173-A2AR plasmid and the 
pBiFC-CC155-A2AR plasmid, were then transfected according to 
Lipofectamine® 2000 protocol instructions where 0.2 µg of constructs plasmid 
were transfected into 1321N1 cells, astrocytoma cell line that endogenously 
express muscarinic M3 receptor, and incubated for 48 hours at 37°C, the 
physiological temperature of mammalian cells, to determine whether the receptor 
protein-BiFC was expressed and the fluorescent signal was detected to confirm 
the homodimerisation of the receptor. Two fusion protein controls, a positive 
control (pBiFC-bFos-VN173 with pBiFC-bJun-VC155) and a negative control 
(pBiFC-bFos-ΔzipVN173 with pBiFC-bJun-VC155), were also used to compare 
the number of cells that has detectable BiFC constructs with the proportion of 
cells that expresses the fusion proteins using fluorescence microscopy. 
 
No fluorescence signal was detected in the constructed protein complexes 
and in positive control only ~5-10 cells. Troubleshooting of the method was 
addressed in two ways: 1) by increasing the concentration of the plasmid DNA 
vectors to 0.4 µg, 0.6 µg, 0.8 µg, 1.2 µg and 2.4 µg; 2) by incubating for 24 
hours at different temperatures 4°C, 25°C and 30°C. No fluorescence signal was 
detected in any of these different conditions, which may be due to the fact that 
the BiFC analysis does not support interaction between the proteins under 
investigation interact in the cell line used. This was addressed by changing the 
type of cell line from 1321N1 to HEK293T cells. Unfortunately, no fluorescence 
was detected in HEK293T cells. 
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Although no fluorescence was detected, we cannot rule out that there is 
an interaction between the A2A receptor as the interaction may still exist between 
the A2A receptor because the creation of the fusion protein may alter the structure 
or interaction face of the target protein or the fluorescence fragments may be 
physically unable to associate. Although the A2A receptor has been documented 
to form homodimers and higher ordered oligomers with the BiFC technique[87, 
177], they did not describe the intensity of the signal nor the number of cells it 
was seen in. They have used different types of cells (CAD) and/or another 
techniques for transfection that had a higher cDNA concentration (10 µg). 
 
3.5 LANCE Ultra assay development and optimization with the 
A2A-BiFC constructs 
Several steps needed to be established before the agonist and antagonist 
of A2A may be tested because the required cell number and stimulation 
conditions can vary for each cell line and for each receptor tested. The first step 
of the assay development consisted of running a cAMP standard curve to 
determine the assay sensitivity and dynamic range of the cAMP kit. This was 
established by preparing serial dilutions of 50 µM standard cAMP in half log 
units from 1 µM to 10 pM (log values: -11 to -6). The assay shows an IC50 value 
for cAMP of 1 nM (see Figure 3.3). The next step was to identify an optimal cell 
density by performing a forskolin and cell density cross-titration experiment; this 
was achieved by forskolin dilutions from 10 mM stock solution in half log units 
from 40 µM to 120 nM (log values: -8 to -3). The cAMP experiments were 
conducted in parallel with the BiFC work and were discontinued when it became 
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clear that troubleshooting the BiFC was problematic. It was deemed unwise to 
continue the Lance studies, which were being performed using the BiFC 
constructs, until such time as the BiFC experiments were able to be successfully 
performed.  
 
 
 
 
 
 
Figure 3.3 cAMP standard curve 
 
Data are presented as mean ± s.e.m of triplicate measures and are representative of three 
independent experiments. Concentration-response curves were analyzed by fitting data to the 
four-parameter logistic equation using GraphPad Prism®. 
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3.6 Computational analyses of the generated TM5-TM5 
ensembles 
The following work aims to develop an ensemble-based coarse-grained 
molecular dynamics (eCG-MD) methodology for the analysis of interactions 
between two GPCR TM helices (see Figure 3.4). To do this, it is necessary 
investigate the computational parameters required to obtain converged results 
computationally and to identify whether these results match the experimentally-
obtained data for the self-association of the TM5 helices of the A2A adenosine 
receptor. 
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Figure 3.4 A screenshot representation of eCG-MD simulation 
(a) At the start of the simulation, (b) at the middle of the simulation and (c) at an end of a 
simulation. 
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3.6.1 Ensembles interacting Interfaces 
Seven simulation sets were tested that included: 1) both wild-type TM5 
and TM2, 2) five types of mutated TM5 (M1775.38A, M1935.54A, M1935.54I, 
Y1975.58A and Y1975.58F). First, the final mean distance between the two helices 
in an ensemble of 50 replicas in each set was used to identify the specific 
interactions between the A2A homodimers. Following the application of the 10Å 
cut-off, 26% of the ensemble formed stable dimers in the wild-type TM5-TM5 
simulations. In the mutated TM5-M1775.38A and in the TM5-M1935.54I 
simulation sets, 16% of the ensemble formed stable dimers while in TM5-
M1935.54A, dimers were detected in 28% of the ensemble. In the mutated TM5- 
Y1975.58A and in the TM5-Y1975.58F, dimers were detected in 16% and 18% of 
the ensembles respectively. For all six of the TM5 simulation sets, the detected 
interactions took place at the same position within the helices, indicating that a 
defined orientation is needed to establish a specific interaction. In the negative 
control (the TM2-TM2 simulation set), 24% of the ensemble resulted in the 
formation of stable dimers but there were no specific interactions identified 
between residues. For all simulations, of those pairwise combinations in which 
dimerisation was identified after the cut-off 10Å had their trajectories combined 
and the results with heat maps of interactions observed at 12Å and 15Å 
compared (see Figure 3.5). The location of the contact interface was then 
mapped by comparison with the crystal structure of A2AR (3EML) on which the 
helices were modelled. 
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Figure 3.5 Contact matrices (heat maps) showing specific interactions between residues, as 
measured by distance, between two A2A helices (“Helix 1” and “Helix 2”) 
For the wild-type TM5-TM5 simulation (a-c) and for the TM2-TM2 negative control (d-f). 
Results shown are the average for each ensemble. Interhelical distances at the 15Å cutoff are 
shown in the top left quarter of panels (a) and (d). Interhelical distances at the 12Å cutoff are 
shown in the top left corner of (b) and (e) and in the lower right quarter of panels (a) and (d). 
Interhelical distances at the 10Å cutoff are shown in the lower right quarter of panels (b) and (e). 
The region shown in the black rectangle in (a) and (d) is magnified in (c) and (f), respectively. 
The five numbered interactions shown in (c) are identified in Table 3. The colour scale indicates 
distance between helices: blue corresponds to 0Å (superposition of the two helical backbones at 
all cutoffs); green corresponds to 5Å (10Å cutoff), 6Å (12Å cutoff), 7.5Å (15Å cutoff); yellow 
corresponds to 7Å (10Å cutoff), 8Å (12Å cutoff), 12Å (15Å cutoff); red corresponds to the cutoff 
distances applied (10Å, 12Å or 15Å).   
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3.6.2 Identification of contact interface for the wild-type TM5-TM5 
homodimer 
After identifying the interacting replicas their trajectories were combined 
in the TM5-TM5 ensemble, the contact interface were identified (the contacting 
residues) by measuring the average interhelical contact distance between the two 
wild-type TM5-TM5 helices (see Figure 3.5a-c) or between the negative control 
TM2-TM2 helices (see Figure 3.5d-f) was determined and results plotted at two 
different distances, 12Å and 15Å as heat maps of interactions. The proximity of 
the wild-type helices is best visualised at 15Å (see Figure 3.5a and c). The 
interacting residues in the wild-type TM5-TM5 simulation are found in the 
bottom third of the C-terminal end of TM5. From the averaged interhelix contact 
matrices, the specific interactions were found to be within the experimentally 
identified M1935.54xxVY1975.58 motif at an interhelical distance of ~8-9Å. The 
methionine at position 1935.54 of helix 1 interacts with the methionine at the same 
position on helix 2, reinforcing the suggestion[64] of its importance in the 
formation of the TM5 homodimer. From Figure 3.5d, it can be seen that the 
distance between TM2-TM2 is close enough to form potential specific 
interactions, however, none were detected in the combined trajectories for this 
negative control. Results obtained at the 15Å cutoff (see Figure 3.5f) were 
random and non-specific, supporting the selection of a minimum cutoff distance 
of 12Å. The frequency of specific interactions identified in the wild-type TM5-
TM5 ensemble was determined by calculating the mean distance for each frame 
of every replica individually. Table 3.1 shows that the five most prominently 
occurring interactions were between M1935.54-M1935.54, V1965.57-Y1975.58, 
Y1975.58-R1995.60, R1995.60-R1995.60 and R1995.60-I2005.61. 
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These findings are consistent with the experimental results[64] 
identifying that the interaction between two wild-type A2A TM5 peptide 
sequences involved amino acid residue M1935.54. These findings are also 
consistent with experimental data showing the formation of A2A receptor 
homodimers using bioluminescence resonance energy transfer (BRET)[86] and 
bimolecular fluorescence complementation (BiFC)[87]. The presence of specific 
interaction between TM2 helices was experimentally investigated and none were 
detected[64, 146]. The eCG-MD simulations produced the same results as 
experimentally obtained findings, with the formation of wild-type TM5-TM5 
dimers involving the M1935.54 residue and no specific interaction detected 
between TM2-TM2 helices in silico. 
 
 
Figure 
label 
Interacting 
residues 
Replica number Mean Distance 
± Standard 
Deviation (in 
Å) 
1 5 10 15 20 25 30 35 40 45 50 
1 M193-M193 0 0 1 1 1 2 2 3 5 6 6 7.59 ± 2.89 
2 V196-Y197 0 1 2 2 2 4 4 6 9 12 13 9.16 ± 2.5 
3 Y197-Y197 0 1 1 1 1 1 2 4 6 7 8 9.11 ± 2.85 
4 Y197-R199 0 1 1 1 1 1 1 3 5 6 6 9.83 ± 3.57 
5 R199-R199 0 1 1 1 1 1 1 3 4 5 5 8.06 ± 2.99 
 
Table 3.1 The number of interactions (hits) for specific interacting 
residues identified in the contact matrices for the wild-type TM5-
TM5 simulation at the 10Å cut-off. 
 
3.6.3 Identification of contact interface for the mutated TM5-TM5 helices 
The identification of the presence of M1935.54 in the wild-type contact 
interface suggested that this residue may play a significant role in how the two 
TM5 helices interact. To investigate this possibility, three sets of ensemble 
simulations were performed that included helices that included mutations at 
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M1775.38 or at M1935.54 (M1775.38A, M1935.54A, and M1935.54I). Two types of 
point mutations were used: (1) the substitution of methionine to alanine; and, (2) 
the substitution of methionine to isoleucine. Investigation of the TM5 peptide 
sequence revealed that two separate PxxxM motifs existed within the same helix, 
with a methionine residue present at M1775.38 as well the methionine residue 
identified at M1935.54. Each of these methionine residues was mutated to alanine. 
M1935.54 was also mutated to isoleucine because a conserved PxxxI motif is 
found in the related family of P2Y receptors at the same location as the 
originally-identified PxxxM motif in A2AR. 
 
Specifically interacting residues in the TM5-M177A simulation set were 
identical to those identified in wild-type TM5-TM5 dimers (see Figure 3.6a) and 
included the M1935.54xxxVY1975.58 motif. M1775.38 was not directly involved in 
the dimerisation between the two helices in any simulation. The specific 
interactions observed in the TM5-M193I5.54 simulation set were almost identical 
to those found in the wild-type but included I1935.54 in the interaction, despite the 
loss of the methionine at position 193 (see Figure 3.6b). In contrast, the TM5-
M193A5.54 mutation completely changed the contact interface of the helices (see 
Figure 3.6c) and the key interacting residues were identified at a similar distance, 
but contained within a newly identified V1965.57YxR1995.60 motif. This provides 
a molecular explanation for the finding that mutation of the full-length A2AR at 
position M1935.54 noticeably alters the monomer:dimer ratio, as observed with 
SDS-PAGE[64]. Mutation of M193A5.54 causes a change in the way in which the 
two helices come together that prevents formation of TM5 homodimers, 
Chapter 3: Development of an integrated experimental-computational approach 
for the characterisation of GPCR dimers 
 99 
emphasizing the importance of the M1935.54 residue in the specificity of TM5-
TM5 dimer formation in vivo. 
 
The identification of the Y1975.58 in the wild-type contact interface as the 
residue with most hits (highest number of occurrence) suggested that this residue 
may play a significant role in how the two TM5 helices interact. To investigate 
this possibility, two sets of ensemble simulations were performed with helices 
mutated at Y1975.58 (Y1975.58A, and Y1975.58F). Two types of point mutations 
were used: (1) the substitution of tyrosine to alanine; and, (2) the substitution of 
tyrosine to phenlalanine, phenylalanine is identical to tyrosine, with the 
exception of the absence of the phosphorylatable hydroxyl group. Thus, a 
phenylalanine mutation is often used to make the residue non-phosphorylated. 
Alanine, on the other hand, lacks the aromatic ring present in tyrosine and 
phenylalanine, so a mutation to alanine effectively removes the tyrosine side 
chain. 
 
The interacting residues in the both ensemble sets TM5-Y197A and 
TM5-Y197F simulation set were identical to those identified in wild-type TM5-
TM5 dimers (Figure 3.7) and included the M1935.54xxxVYxR1995.60 motif but 
with more residues at longer distances as seen in the TM5-M193A mutation. 
Mutation of Y1975.58A/F does not causes a change in the way in which the two 
helices come together and does not effect the formation of TM5 homodimers, 
emphasizing that the Y1975.58 may not be a key residue in the specificity of 
TM5-TM5 dimer formation in vivo but rather only a part of the interacting motif 
in the wild-type homodimer. 
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Figure 3.6 Contact matrices (heat maps) showing specific interactions between two mutated 
A2A TM5 helices (“Helix 1” and “Helix 2”) with the following residues mutated: M177A (a), 
M193A (b) and M193I (c) 
Results shown are the average for each ensemble. Interhelical distances at the 15Å and 12Å 
cutoff distances are shown in the top left quarter and in the lower right quarter of panels (a-c), 
respectively. The colour scale is as indicated in Figure 3.4. Circles indicate areas with key 
interhelical contacts. The identified amino acid interactions are numbered as follows: (1) 
M1935.54 with M1935.54; (2, 3) V1965.57 with Y1975.58 and Y1975.58 with Y1975.58; (4) Y1975.58 
with I2005.61 and R1995.60 with R1995.60; (5) L1925.53 with I1935.54, V1965.57 with Y1975.58 and 
Y1975.58 with R1995.60, (6) Y1975.58 with I2005.61 and Y1975.58 with R1995.60; and (7) R1995.60 
with R1995.60. 
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Figure 3.7 Contact matrices (heat maps) showing specific interactions between two mutated 
A2A TM5 helices (“Helix 1” and “Helix 2”) with the following residues mutated: Y197A (a) 
and Y197F (b) 
Results shown are the average for each ensemble. Interhelical distances at the 15Å and 12Å 
cutoff distances are shown in the top left quarter and in the lower right quarter of panels (a-c), 
respectively. The colour scale is as indicated in Figure 3.4. Circles indicate areas with key 
interhelical contacts. The identified amino acid interactions are numbered as follows: (1) 
M1935.54 with M1935.54; (2) V1965.57 and A1975.58 with A1975.58 and A1975.58; with I2005.61 and 
R1995.60 with R1995.60; (3) R1995.60 with R1995.60; (4) M1935.54 with M1935.54; (5) V1965.57 and 
F1975.58 with F1975.58 and F1975.58; with I2005.61 and R1995.60 with R1995.60; (6) R1995.60 with 
R1995.60.  
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3.7 Statistical analyses of the computationally generated 
ensemble sets 
This portion of the work aims to investigate the computational parameters 
required to obtain converged results using error analysis to determine the 
ensemble size and individual replica simulation run-time required. 
 
The five different ensembles, one for each A2A receptor simulation set, 
were run independently in CG-MD simulations for the total run time of 500 ns. 
These data, which included both wild-type and mutated helix sequences, were 
used to investigate whether variations in the optimal replica number required 
would occur between different simulation sets. This information was used to 
identify the minimum replica number required to achieve convergence for any 
given simulation set. At the start of the simulation, the behaviour of the TMs was 
monitored and the TM helices were observed to diffuse freely in the DPPC lipid 
bilayer. The kernel density estimation was used to estimate the probability of the 
mean distance between the two wild-type TM5 helices at t = 0 and at increments 
of 100 ns up to completion of the simulation at 500 ns across the 50 replica 
ensemble is shown in Figure 3.8. At t = 0, the two helices are at their starting 
positions 40Å (4.0 nm) apart. At t = 500 ns, the mean distance between the 
helices has adopted a normal distribution with a mean distance of ~16Å between 
them. The intermediate time points show the redistribution of the distance from 
the starting point at t = 0 to the final mean distance between the helices at 500 ns. 
A graphical representation of the number and time of interactions observed in 
each replica for the wild-type TM5-TM5 simulation within the ensemble of 50 
replicas is shown in Figure 3.9; these were produced by a locally written code. 
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Four of the 50 replicas showed no contact between the helices, which gives rise 
to the small peak at 40Å at the end of the replica run (t = 500 ns) in Figure 3.7. 
Three of the replicas began to show contact towards the end of the run; this 
corresponds to the smaller peak seen at 30Å at t = 500 ns in Figure 3.7. 
 
 
 
Figure 3.8 Distribution of the mean distance between the two TM5-TM5 wild type helices at 
0, 100, 200, 300, 400 and 500 ns in all 50 replicas. 
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Figure 3.9 The number and timing of pairwise interactions for each of the 50 replicas 
within the wild-type TM5-TM5 dimer ensemble are shown 
The x and y axes are linear and represent run length from 0 to 500 ns and the number of 
interaction events from 0 to 250 counts, respectively.  
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3.7.1 The optimal replica number required 
The optimal replica number required for simulations was identified by 
plotting the mean distance between the two helices of each of the ensemble sets 
against the replica number (see Figure 3.10a). This revealed that there is no 
statistically significant difference in the mean distance as a function of replica 
number. However, a decrease in the error of the mean is observed with 
increasing ensemble size (see Figure 3.10b) and it can be seen that the rate of 
decrease in the error slows after approximately 15 replicas have been included in 
the ensemble. For each of the five sets, larger ensembles provide less variation in 
the error of the mean and an ensemble of 30 replicas represents a good 
compromise between computational effort and minimisation of the error in the 
mean distance calculated. From Figure 3.10, it can be seen that an ensemble of 
30 replicas is sufficient to achieve convergence. 
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Figure 3.10 Variation in (a) the mean distance between TM helices and (b) the error 
(standard deviation) is shown as a function of the number of replicas performed 
For the following simulation sets: () wild-type TM5-TM5 helices, (n) M177A-mutated TM5-
TM5 helices, (▲) M193A-mutated TM5-TM5 helices, (▼) M193I-mutated TM5-TM5 helices, 
and (®) wild-type TM2-TM2 helices.  
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3.7.2 The minimum run time length required  
The minimum run time length required for each replica in an ensemble 
was estimated by calculating the mean distance and the standard deviation of the 
mean within the 50 replicas for simulations of varying duration (0, 100, 200, 300, 
400 and 500 ns). The standard deviation of the mean provides an estimate of the 
error associated with the finding of an interaction between two helices.  
Figure 3.11a shows a significant effect of run length on both mean 
distance and standard deviation and reflecting the time required for interactions 
to take place. For four of the five simulation sets, the standard deviation 
increases as a function of time, with the rate of increase slowing as the run length 
becomes longer. In contrast, no change in the standard deviation over time is 
seen in the TM2-TM2 set (Figure 3.11b). The low standard deviation between 
the two TM2 helices indicates that the mean distance between the helices was 
about the same throughout the simulation. Interestingly, the TM2-TM2 mean 
distance was close enough to form potential specific interactions, however, none 
were detected in the combined trajectories for this negative control, this finding 
agrees with the experimental findings where TM2 homodimers could not be 
detected[146]. The absence of an increase in error in the mean distance as a 
function of time may serve as an indicator of an absence of interaction between 
two helices within an ensemble. From the figure, it can be concluded that an 
ensemble run for a simulation time of 300 ns is sufficient to achieve 
convergence. 
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Figure 3.11 Variation in (a) the mean distance between TM helices and (b) the error 
(standard deviation) is shown as a function of the run length 
For the following simulation sets: () wild-type TM5-TM5 helices, (n) M177A-mutated TM5-
TM5 helices, (▲) M193A-mutated TM5-TM5 helices, (▼) M193I-mutated TM5-TM5 helices, 
and (®) wild-type TM2-TM2 helices.  
  
Chapter 3: Development of an integrated experimental-computational approach 
for the characterisation of GPCR dimers 
 109 
3.8 Summary 
From the computational eCG-MD results, specific interactions involving 
the PxxxM motif of TM5 were identified, specifically, at the M1935.54 residue 
within that motif. The eCG-MD method, therefore, accurately identified residues 
shown experimentally to be involved in TM5 homodimerisation. The M1935.54 
was found to interact with the other M1935.54 on the other helix. The role of 
M1935.54 was further investigated by characterizing the effect of mutation on the 
methionine, using the M1935.54A mutation. From this, it was clear that the 
contact interface of the helices was completely changed and that the key 
interacting residues identified in the wild-type conformation had moved to a new 
position, preventing formation of TM5 homodimers. The results provided a 
molecular explanation for the experimental finding that the M1935.54A mutation 
alters the monomer:dimer ratio at a level of detail that could not be determined 
biophysically and would require structural biology studies to confirm 
experimentally. M1775.38 was not involved in the interaction between the two 
helices and by mutating it the contact interface was not affected. The M193I5.54 
mutation had no effect on the residues involved in contact interface; they were 
identical to those found in the wild-type but, additionally, included I1935.54 in the 
interaction, despite the loss of the methionine at position 193. Mutation of 
Y1975.58A/F had no effect on the way in which the two helices came together, 
emphasizing that the Y1975.58 may not be a key residue in the specificity of 
TM5-TM5 dimer formation but rather, may only a part of the interacting motif in 
the wild-type homodimer. 
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These results clearly demonstrate that sufficient conformational sampling 
is required in coarse-grained MD to obtain reproducible and reliable results. In 
the eCG-MD simulations, it was noted that several of the replicas within the 
ensemble failed to show any interactions and that a number of others began to 
interact late in the simulation at a point when accurate estimates of distance 
could no longer be achieved. A single trajectory simulation, particularly if either 
of these circumstances were to occur, would give inaccurate and potentially 
misleading results. Error analysis was used to determine appropriate choices for 
ensemble size and run length. For ensemble size, the rate of change in the 
standard deviation of the mean distance between helices decreased with 
increasing replica size and found that approximately 30 replicas was sufficient 
per ensemble to obtain reproducible results. For run length, the rate of increase in 
the standard deviation of the mean distance between helices increased with 
increasing run length, but that the rate of increase slowed substantially after 
approximately 300 ns. Interestingly, the negative control (TM2-TM2) included in 
the eCG-MD simulations showed no variation in the standard deviation of the 
mean distance between helices as a function of run length and a low standard 
deviation with a very rapid decrease to a constant value at an ensemble size of 
~15 replicas. This behavior was notably different from simulations in which 
interactions were identified and provides a means of confirming the absence of 
interaction. 
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Chapter 4 
Computational comparison with 
experimental structural data 
 
 
4.1 Introduction 
In order to assess the validity of the computational method, it is necessary 
to compare the results with experimental values that exist. The computational 
results obtained for the A2A receptor homodimers (see Chapter 3) closely match 
the experimental biophysical data and provide information about the nature of 
the contact interface between the two helices that cannot be determined 
experimentally. This chapter aims to determine whether the eCG-MD method 
developed in Chapter 3 gives findings in agreement with experimentally-
obtained structural data. To do this, CG structures will be converted to atomistic 
structures and compared with existing structural data.  Although no structural 
data exist yet for A2A dimers, this approach may allow hypotheses to be drawn 
about the molecular nature and possible role of the interactions between the 
dimeric TM5-TM5 helices studied in Chapter 3. 
 
Dimerisation in Class A GPCRs involves the transmembrane domains, as 
opposed to Class C GPCRs, where dimerisation is mediated by the large N 
terminal domain of the protein[178]. Three Class A GPCR dimeric crystal 
structures were identified that fulfilled the following criteria: 1) the 
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crystallographic asymmetric unit is a dimer; 2) the software-determined (PISA) 
quaternary structure is a dimer; and, 3) the dimeric quaternary structure has been 
confirmed functionally. Three class A GPCRs fit this criteria and have 
experimentally-obtained structural data. These were chosen evaluate the method 
developed, these include: rhodopsin, the CXCR4 chemokine receptor and the β1 
adrenergic receptor (β1AR), their corresponding TM helices (listed in Table 2.3) 
were constructed as described in section-2.2.3 of materials and methods and used 
in ensemble-based simulations. 
 
4.2 Computational identification of interacting interfaces: 
rhodopsin  
Rhodopsin has been shown to exist in a native oligomeric form[29] and 
an atomic model of the rhodopsin dimer has been proposed as a working model 
for G protein-coupled receptors[28]. This model, 1N3M, is the only GPCR dimer 
for which structural data exist. Three contact points between the rhodopsin 
monomers have been reported. The first is considered to be the strongest, with 
the largest contact area (578Å2) and is located between TM4 and TM5. The 
second exhibits a contact area of 333Å2 and is located between TM1 and TM2. 
The third contact point is considered the weakest interaction and is found 
between rows of dimers at the extracellular ends of TM1 with a contact area of 
146Å2[28, 44]. 
 
Two heterologous simulations sets were run to identify whether contact 
interfaces could be identified for either: rhodopsin helices TM1 and TM2 and 
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rhodopsin helices TM4 and TM5.  For each set, the same method used to analyse 
the A2AR simulation sets was applied to investigate and analyse the helix-helix 
dimerisation in the simulations of rhodopsin First, the final mean distance 
between the two helices in an ensemble of 50 replicas in each set was used to 
identify the specific interactions between the rhodopsin homodimers. Following 
the application of the 10Å cut-off, 14% of the ensemble formed stable dimers in 
the TM1-TM2 simulations. In the TM4-TM5 simulation set 32% of the ensemble 
formed stable dimers, confirming that our computational method is able to 
produce results in agreement with structural data. In each set, the mean distance 
between helices was ~7.6-8Å (see Table 4.1). The mean distance between 
specific interacting residues in the TM1-TM2 simulation (see Figure 4.1a) is 
further apart than the mean distance between specific interacting residues in the 
TM4-TM5 simulation (see Figure 4.1b). 
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Receptor Helices Interacting residues 
Crystal structure 
distance (Å) 
Mean Distance (Å) ± 
Standard deviation 
Rhodopsin TM1-TM2 F1271.47 - L2182.44  15.28 14.2 ± 4.07 
M1191.39 - D2242.50 9.01 10.32 ± 3.1 
TM4-TM5 F4184.48 - L5215.51 12.07 9.18 ± 3.24 
T4194.49 - L5215.51 14.77 8.13 ± 1.96 
G4154.45 - F5255.55 16.44 7.5 ± 2.3 
H4114.41 - Q5305.60 17.64 9.06 ± 3.34 
CXCR4 TM5-TM5 F2015.40 - V1985.37 7.37 15.55 ± 3.34 
F2015.40 - Q2005.39 11.03 13.7 ± 1.46 
F2015.40  - F2015.40 7.91 13.6 ± 2.89 
F2015.40 - Q2025.41 8.72 14.93 ± 3.13 
F2015.40 - I2045.43 12.14 13.11 ± 3.37 
F2015.40 - M2055.44 10.6 12.6 ± 4.96 
β1AR TM1-TM1 W401.31 - A421.33 12.21 15.28* 
W401.31 - S451.36 12.41 17.5* 
W401.31 - L461.37 13.84 18.3* 
M441.35 - L461.37 9.8 13.46* 
A491.39 - M481.38 8.86 5.39* 
L531.44 - M481.38 12.19 5.01* 
L531.44 - V511.40 10.75 4.9* 
L531.44 - V521.41 11.13 5.2* 
L541.45 - V511.40 13.9 5.09* 
TM4-TM5 L1594.43 - Y2315.58 ND** 9.01 ± 2.22 
W1664.50 - Y2275.62 ND** 7.9 ± 1.99 
Table 4.1 The comparison of distance of the identified interacting 
residues† from contact matrix graphs. 
The comparison of distance of the identified interacting residues† from contact matrix graphs 
of the rhodopsin, CXCR4 and β1AR helices and the crystal rhodopsin dimer (1N3M), CXCR4 
dimer (4GPO) and the β1AR dimer (3ODU). 
†  Distances are measured from backbone to backbone. 
* Interactions were detected in only one replica in the ensemble. 
** Not Determined (ND): The distances between TM4 and TM5 could not be measured due to 
the orientation of the dimer in the 4GPO crystal structure, which is submitted showing the TM1-
TM2 dimer interface.  
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4.2.1 Identification of the contact interface for the rhodopsin homodimer 
Following screening, extending the cutoff to 15Å in the averaged 
interacting simulation revealed an increase in the number of interactions 
observed and presented the strongest interacting residues. The most prominent 
interactions within the 12Å cutoff with about ~8-9Å interhelical distances 
present were between the residues was found in the Y1181.40MFxLIxxxF1271.47 
motif in TM1 with L2182.44NLxxxDL2252.51 motif in TM2 (see Figure 4.1a). 
These motifs are found in the middle of the TM1 and TM2 helices. The most 
prominent interactions within the 12Å cutoff with about ~7.6-8Å interhelical 
distances present were between the residues was found in the 
H4114.41xxMGVxFT4194.49 motif in TM4 with residues 
L5215.51xxxFxxYGQ5305.60 motif in TM5 (see Figure 4.2b). TM4 motif is found 
in the upper third of the TM at cytoplasmic side and the TM5 motif is found in 
the bottom third of the N-terminal end of TM5. 
 
These findings are consistent with the first physical results of rhodopsin 
receptor dimerisation that emerged from atomic-force microscopy[29], that 
structure showed that the contact area between TM4-TM5 is the strongest and 
largest contact area, in our results it showed the shortest distance between TM 
helices. 
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Figure 4.1 Contact matrices (heat maps) between two rhosopsin helices 
Contact matrices (heat maps) between two rhosopsin helices showing specific interactions 
between TM1 (Helix 1) and TM2 (Helix 2) (a) and between TM4 (Helix 1) and TM5 (Helix 2) 
(b). Results shown are the average for each ensemble. The color scale is as indicated in Figure 
3.4. Circles indicate areas with key interhelical contacts. The identified amino acid interactions 
are numbered as follows: 1) F1271.47 with L2182.44; 2) L1221.42 with L2202.46, I1231.43 with 
L2182.44 and N2192.45 with L2202.46; 3) Y1181.38 with D2242.50, M1191.39 with D2242.50, F1201.40 
with D2242.50 and F1201.40 with L2252.51; 4) F4184.48 with L5215.51 and T4194.49 with L5215.51; 5) 
F4184.48 with F5255.55; 6) M4144.44 with F5255.55, G4154.45 with F5255.55 and V4164.46 with 
F5255.55; 7) H4114.41 with Y5285.58, H4114.41 with G5295.59 and H4114.41 with Q5305.60.  
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4.3 Computational identification of interacting interfaces: 
CXCR4  
The crystal structure of the CXCR4 chemokine receptor (3ODU) bound 
to an antagonist small molecule IT1t has been reported and reveals a homodimer 
with an interface involving TM helices 5 and 6. They report that this dimer is 
mainly held by hydrophobic interactions involving residues: L1945.33, V1975.36, 
V1985.37, F2015.40, M2055.44 and L2105.49[150]. The first step was to investigate the 
interactions between TM helices in the CXCR4 receptor and to identify the 
formation of stable dimers with specific interactions (see Figure 4.2). A 
heterologous simulation between TM5 and TM6 was performed and there were 
no interactions identified (see Figure 4.2a) this can be explained by the fact that 
CXCR4 is able to form homodimers in the absence of ligand[179] that are unable 
to be dissociated by a peptide derived from TM6[180], suggesting that in 
unliganded CXCR4, the dimer interface may reside between TM5 and TM5, in a 
manner analogous to the A2A receptor. Next, a CXCR4 TM5-TM5 simulation 
was run. In the TM5-TM5 simulation set 8% of the ensemble formed stable 
dimers. The mean distance between helices was ~11-13Å (see Table 4.1). 
 
4.3.1 Identification of the contact interface for the CXCR4 homodimer 
Following screening, the cutoff to 15Å was extended in the averaged 
interacting simulations, which revealed an increase in the number of interactions 
observed and presented the strongest interacting residues. Identification of the 
contact interface for the CXCR4 homodimers where the most prominent 
interactions was established from the averaged interhelix contact matrices, the 
formation of dimers with specific interactions between F2015.40 on one TM and 
Chapter 4: Computational comparison with experimental structural data 
 118 
the following six residues in the other TM: V1985.37, Q2005.39, F2015.40, Q2025.41, 
I2045.43 and M2055.44 (see Figure 4.2b). These residues are found in the upper 
third of the N-terminal end of TM5. 
 
 
 
 
Figure 4.2 Contact matrices (heat maps) between two CXCR4 helices 
Contact matrices (heat maps) between two CXCR4 helices showing specific interactions between 
TM5 (Helix 1) and TM6 (Helix 2) (a) and between TM5 (Helix 1) and TM5 (Helix 2) (b). The 
identified amino acid interactions are numbered as follows: 1) F2015.40 with V1985.37, Q2005.39, 
F2015.40, Q2025.41, I2045.43 and M2055.44.  
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4.4 Computational identification of interacting interfaces: β1AR 
Two alternating dimer interfaces have been proposed from the crystal 
structure of the ligand-free basal state of the β1 adrenergic receptor (β1AR) 
(4GPO) that were packed in parallel arrangement within the lipid bilayer. The 
first involves TM1, TM2, extracellular loop 1 and the C-terminal H8; the second 
involves TM4, TM5 and the intracellular loop 2. In the first dimer, the TM1-
TM2-H8 dimer, the interactions identified within the TM helices were mainly 
through TM1 and the interacting residues included: Q381.29, Q391.30, A421.33, 
L461.37, L491.40, L501.41, V521.43, L531.44 and L541.45 and from TM2: P962.59, 
A992.62, T1002.63 and V1032.66 these interactions are mainly hydrophobic and van 
dar Waals. The second dimer interface included residues from both TM4; 
L1714.44; and TM5: R2055.36, A2065.37, A2105.41, I2185.49 and R2295.60[151]. 
 
Two heterologous simulations between the β1AR helices: TM1 and TM2 
and between TM4 and TM5 were run to identify whether contact interfaces could 
be identified for either. No stable dimers were formed in the TM1-TM2 
simulation (see Figure 4.3a) that led to the possibility that the contact interface 
was maybe between two TM1’s from two receptors as the interactions were 
mainly from TM1. This possibility was investigated and a TM1-TM1 simulation 
was run and identified a stable dimer in only one replica in the ensemble, in a 2% 
of simulations (see Figure 4.3b). In the TM4-TM5 simulation, stable dimers were 
formed at 14% of simulations (see Figure 4.3c). 
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Figure 4.3 Contact matrices (heat maps) between two β1AR helices 
Contact matrices (heat maps) between two β1AR helices showing specific interactions between 
TM1 (Helix 1) and TM2 (Helix 2) (a), between TM1 (Helix 1) and TM1 (Helix 2) (b) and 
between TM4 (Helix 1) and TM5 (Helix 2) (c). Results shown are the average for each ensemble. 
The colour scale is as indicated in Figure 3.4. Circles indicate areas with key interhelical 
contacts. The identified amino acid interactions are numbered as follows: in (b) 1) W401.31 with 
A421.33, S451.36 and L461.37; 2) M441.35 with L461.37; 3) A491.39 with M481.38; 4) L531.44 with 
M481.38; 5) L531.44 with M481.38, V511.40 and V521.41; 6) L541.45 with V511.40; (c) 1) K1594.43 with 
Y2275.58; 2) W1664.50 with Y2315.62.  
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4.4.1 Identification of the contact interface for the β1AR homodimer 
In the interacting replica of TM1-TM1 ensemble the contact interface 
was identified by measuring the average interhelical contact distance between the 
two TM1 helices the mean distance between helices was ~5-18Å. The interface 
included residues W401.31, M441.35, A491.39, L531.44 and L541.45 from one TM1 
with A421.33, S451.36, L461.37, M481.38, V511.40 and V521.41 in the other TM1 
(Figure 4.3,b) these residues are located in the center of TM1. 
 
In the TM4-TM5 ensemble, the contact interface was identified (the 
contacting residues) by measuring the average interhelical contact distance 
between the TM4-TM5 helices which was ~7-8Å (Figure 4.3c) and the specific 
interactions identified were between K1594.43 and Y2275.58 and between W1664.50 
and Y2315.62 these interactions are located in the middle of TM4 and at the end of 
TM5. 
 
4.5 Atomistic representation and proposed nature of interactions 
CG simulations lack the specific details needed to describe the nature and 
type of the interactions that might take place when the two TM helices are within 
10Å of each other because in the CG simulation a small group of atoms is treated 
as a single particle in a 4:1 ratio. To try to understand what type of interactions 
were involved in the formation of stable dimers the combined representative CG 
dimer structures were converted into representative atomic structures to enable a 
measurement of distance between atoms[171] allowing hypotheses to be drawn 
about the molecular nature and possible role of the interactions between dimeric 
helices. The occurrence of Cα-H......O contacts as a function of the interhelical 
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axial distance in the database are between 6 and 12Å with an average of 
8.9Å[175]. 
 
4.5.1 The TM5-TM5 homodimer of A2A 
A representation of the converted atomistic wild-type A2A TM5 dimer is 
seen in Figure 4.4. Using this atomistic representation, the presence of possible 
electrostatic interactions or hydrogen bonding was investigated by measuring the 
distance between the specific interacting residues. The interaction between the 
two methionine residues (M1935.54-M1935.54) and between valine and tyrosine 
(V1965.57-Y1975.58) are likely to correspond to van der Waals interactions. 
Y1975.58 in helix 1 and Y1975.58 in helix 2 each interact as hydrogen donor and 
acceptor in the dimer, forming bonds between the peptide backbone and the 
tyrosine side chain (see Figure 4.4). As the measurement of these distances is 
longer than the optimal hydrogen bond distance, 2.7Å, such hydrogen bonds are 
more likely to be formed backbone-to-side-chain because their interhelical 
distance of 8Å is above the 7.6Å limit of backbone-to-backbone 
interactions[175]. There are presently no structural data with which to compare 
these eCG-MD results. 
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Figure 4.4 Atomistic representation of the pairwise interactions identified from the wild-
type TM5-TM5 ensemble  
The representative mean distance is shown in the figure and the mean distance + SD for all hits 
detected per pair is shown in Table 4.1. All distances between interacting amino acids are 
calculated from side chain to side chain. 
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4.5.2 The rhodopsin homodimer 
The rhodopsin dimer model (1N3M), shown in Figure 4.5a, reveals that 
there is a greater interface area between TM4 and TM5 than between TM1 and 
TM2. The specific interacting residues identified from the atomistic 
representation obtained using the eCG-MD computational method developed in 
Chapter 3 are distributed throughout the length of TM1 and TM2 but restricted to 
the bottom third of TM4 and TM5, with respect to the intracellular face of the 
receptor (see Figure 4.5b-e). A comparison of the eCG-MD results with the TM1 
and TM2 contact interface of 1N3M is shown in Figure 4.5b and c, respectively. 
The measured distance between the hydrogen on the COOH group of M1191.39 
and the double-bonded oxygen of the COOH group on the side chain of D2242.50 
is 10.32 + 3.21Å in the eCG-MD model (see Figure 4.5b), similar to 9.01Å in 
1N3M (Figure 4.5c). Measurement of the distance between F1271.47 and L2182.44 
is 14.20 + 4.07Å in the model and 15.28Å in 1N3M. F1271.47 and L2182.44 are 
located towards the bottom of their respective helices, a position that is 
constrained by the first intracellular loop of rhodopsin in 1N3M, but not in the 
eCG-MD model. Similar conservation of distance was identified between 
interacting residues in TM4 and TM5 (see Table 4.1).  
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Figure 4.5 Atomistic structures of the rhodopsin dimer 
Atomistic structures of the rhodopsin dimer (a) Atomistic structure of the rhodopsin dimer model 
(1N3M) viewed from above, with the TMs used for simulations identified by color as follows: 
TM1 (blue), TM2 (red), TM4 (purple) and TM5 (orange). Representative TM structures were 
obtained from the means of all replicas in which interactions were detected. The representative 
and model structures of TM1-TM2 are shown in (b) and (c), respectively. The representative and 
model structures of TM4-TM5 are shown in (d) and (e), respectively. Specific interactions were 
identified in TM1-TM2 simulations (M1191.39 with D2242.50 and F1271.47 with L2182.44) and in 
TM4-TM5 simulations (H4114.41 with Q5305.60, G4154.45 with F5255.55, F4184.48 with L5215.51 and 
T4194.49 with L5215.51). Table 4.1 shows a comparison of the distances between specific atoms in 
interacting residues of the representative structures and the distances between the same atoms in 
the model structure.  
TM1$TM2$
TM5$ TM4$
a	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4.5.3 The CXCR4 homodimer 
The eCG-MD studies of CXCR4 identified novel interactions in the 
homodimer between TM5 and TM5; these were visible but previously 
unidentified in the CXCR4 (3ODU) dimer (see Figure 4.6). This is similar to 
what was seen for A2A, but the interacting residues in CXCR4 are closer to the 
extracellular side of the membrane than in A2A. A comparison of the mean 
distance between interacting residues obtained from the simulations with the 
distance measured between the same residues in the crystal structure shows a 
similar conservation of distance, particularly between interacting residues further 
down the helix. This suggests a contribution of the loops in influencing 
interactions towards the ends of the helices, as was seen for rhodopsin. 
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Figure 4.6 Atomistic structures of the CXCR4 dimer 
Atomistic structures of the CXCR4 dimer (a) Atomistic structure of the CXCR4 dimer model 
(3ODU), with the TMs used for simulations identified by colour where is TM5 (pink). 
Representative TM structures were obtained from the means of all replicas in which interactions 
were detected. The representative and model structures of TM5-TM5 are shown in (a) and (b), 
respectively. Specific interactions were identified in TM5-TM5 simulations (F2015.40 with 
V1985.37, Q2005.39, F2015.40, Q2025.41, I2045.43 and M2055.44). Table 4.1 shows a comparison of the 
distances between specific atoms in interacting residues of the representative structures and the 
distances between the same atoms in the model structure.  
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4.5.3 The β1AR homodimer 
Like rhodopsin, contact interfaces between TM1 and TM2 and between 
TM4 and TM5 had been proposed for the β1 adrenergic receptor. However, using 
our method it was possible to identify a contact interface between TM1 and 
TM1, rather than between TM1 and TM2. The conversation of distance between 
interacting residues and the distance between the same residues in the crystal 
structure is difficult to compare given the interactions were only identified in one 
replica, however, the measurements are in agreement with those of the crystal 
structure within the limits of error calculated from other simulations. The eCG-
MD data suggest that the TM4-TM5 contact interface, and the four specific 
amino acids identified within it, may constitute the principal dimer interface in 
β1AR homodimers. It was not possible to compare the distances obtained in the 
TM4-TM5 simulation with those measured in the crystal structure 4GPO, which 
had been submitted with the orientation of the dimer showing the proposed TM1-
TM2 interface. 
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Figure 4.7 Atomistic structures of the β1AR dimer 
Atomistic structures of the β1AR dimer (a) Atomistic structure of the β1AR dimer model (4GPO), 
with the TMs used for simulations identified by colour as follows: TM1 (pink), TM4 (red) and 
TM5 (blue). Representative TM structures were obtained from the means of all replicas in which 
interactions were detected. The representative and model structures of TM1-TM1 are shown in 
(a) and (b), respectively. The representative and model structures of TM4-TM5 are shown in (c). 
Specific interactions were identified in TM1-TM1 simulations (W401.31 with A421.33, S451.36 and 
L461.37; M441.35 with L461.37; A491.39 with M481.38; L531.44 with M481.38; L531.44 with M481.38, 
V511.40 and V521.41; L541.45 with V511.40) and in TM4-TM5 simulations (K1594.43 with Y2275.58; 
W1664.50 with Y2315.62.).   
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4.6 Summary 
To validate the results obtained using the ensemble-based CG-MD 
computational methodology, it was necessary to compare the computational 
results with the structural experimental data that existed for other GPCRs. In this 
chapter the eCG-MD method was tested on three GPCRs that fit these criteria. 
First, the rhodopsin dimer for which crystallographic data had identified contact 
interfaces between TM1 and TM2 and between TM4 and TM5. Ensemble CG-
MD confirmed dimerisation and the identification of specific interactions within 
each of these heterologous TM pairs. There is a striking convergence between 
the distances predicted computationally and those calculated from 1N3M, 
particularly for specific interactions between TM1 and TM2, showing that the 
method is able to provide accurate and precise predictions in agreement with 
experimental findings. The eCG-MD method is also able to identify novel 
interfaces as seen in the second (CXCR4) and third (β1AR) cases studied, where 
a novel interface in CXCR4 between TM5 and TM5 and a novel interface in 
β1AR between TM1 and TM1 were identified, in addition to confirming the 
previously identified contact interface between TM4 and TM5 in the β1AR. The 
β1AR has been shown to form transient interactions whereas the β2 adrenergic 
receptor can form stable oligomers[181]. The ability of the eCG-MD 
methodology to detect a stable dimer of TM1-TM1 in the β1AR shows the value 
of ensemble-based simulations for the identification of transient interactions. 
This computational methodology was also able to provide insights into the 
molecular nature of the contact interface between the two TM5 helices of the A2A 
receptor, something that was unable to be provided by the available biophysical 
data.  
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Chapter 5 
Creation and computational analyses 
of TM helix-helix interactions in A2A 
 
 
5.1 Introduction 
As mentioned previously, a computational method for analyzing GPCR 
interfaces, eCG-MD, has been developed. It was tested on specified TM helices 
of four types of GPCRs, all which had good experimental data in which to 
validate the method.  The first case tested was that of homomeric A2A receptors. 
The fifth transmembrane domain (TM5) that was identified to be in involved in 
the self-association by far-UV CD spectroscopy and SDS-PAGE using synthetic 
peptides corresponding to the different transmembrane domains[64] was studied 
through the developed computational method, which gave results consistent with 
the experimental data. This chapter aims to apply the eCG-MD methodology 
described in Chapter 3 and validated in Chapter 4, to identify additional helix-
helix interactions between the seven TM helices of A2A and to compare these 
results to the experimentally-obtained data for the self-association of the helices 
of the A2A adenosine receptor[147].  
 
There are 21 possible heterologous pairs and seven possible homo-
interactions; the TM sequences used for this study are found in Table 2.2.  All 
combinations of possible helix-helix interactions were examined in silico in 26 
different ensemble sets. The final mean distance between the two helices in an 
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ensemble of 50 replicas in each set was used to identify the specific interactions 
between the A2A homo/heterodimers in all the simulation sets run. 
 
5.2 Interacting interfaces of the TM5 pairwise ensembles 
Six simulation sets were tested that included: 1) TM5-TM1; 2) TM5-
TM2; 3) TM5-TM3; 4) TM5-TM4; 5) TM5-TM6 and 6) TM5-TM7. Following 
the application of the 10Å cut-off, 18% of TM5-TM1 ensemble formed stable 
dimers interacted and spontaneously formed homodimers, whereas in the TM5-
TM2 ensemble 32% formed stable dimers. Interactions in the TM5-TM3 
ensemble were seen in 8% of simulations. 16% of TM5-TM4 ensemble was 
found to interact and form stable dimers. The TM5-TM6 ensemble stable dimers 
were seen in 14% of the total simulations. In TM5-TM7 ensemble 12% were 
discovered to interact and form stable dimers. For all simulations, of those 
pairwise combinations in which dimerisation was identified after the cut-off 10Å 
had their trajectories combined and the results with heat maps of interactions 
observed at 12Å and 15Å compared (see Figure 5.1). The location of the contact 
interface in TM5 with the other helices was then mapped by comparison with the 
crystal structure of A2AR (3EML) on which the helices were modelled. 
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Figure 5.1 Contact matrices showing specific pairwise interactions between TM5 and an 
A2A helix 
Contact matrices (heat maps) between two A2A helices showing specific interactions between 
TM1 (Helix 1) and TM5 (Helix 2) (a), between TM2 (Helix 1) and TM5 (Helix 2) (b). between 
TM3 (Helix 1) and TM5 (Helix 2) (c), between TM4 (Helix 1) and TM5 (Helix 2) (d), between 
TM6 (Helix 1) and TM5 (Helix 2) (e) and between TM7 (Helix 1) and TM5 (Helix 2) (f). The 
colour scale is as indicated in Figure 3.4. Circles indicate areas with key interhelical contacts.  
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5.2.1 Identification of the contact interfaces of the TM5 pairwise ensembles 
After identifying the interacting replicas in all sets, their trajectories were 
combined and the contact interface residues were identified by measuring the 
average interhelical contact distance between the two helices as explained 
previously in section 3.7.2 and results plotted at the two different distances, 12Å 
and 15Å as heat maps of interactions. 
 
The most prominent interactions within the averaged 12Å cutoff with an 
interhelical distances of about ~8-10Å in the TM5-TM1 ensemble involved the 
proline and methionine residues of the P1895.50xxxM1935.54 conserved motif 
were part of the interacting residues. The identified interacting amino acids 
between the TM1 and TM5 helices are: 1) A171.43 with P1895.50; 2) A201.46, 
I211.47 with M1935.54; 3) N241.50 with V1965.57, Y1975.58; 4) C311.54 with R1995.60 
(see Figure 5.1a). In TM5-TM2 ensemble no strong interactions were detected 
and only one interaction weak interaction between the two helices was detected 
between 5) F442.42 with Y1975.58 (see Figure 5.1b). The identified interactions in 
the TM5-TM3 ensemble were between residues: 6) L873.36 with L1915.52; 7) 
Q893.38 with L1915.52 and L1945.55; and 8) F933.42 with G1955.56, V1965.57, 
Y1975.58, L1985.59, R1995.60 and I2005.61 (see Figure 5.1c).  Residues in TM5-
TM4 ensemble are: 9) W1294.50 with V1965.57 and Y1975.58; 10) F1334.54 with 
M1935.54 (see Figure 5.1d). Both the proline and methionine in the 
P1895.50xxxM1935.54 motif were involved in the TM5-TM6 ensemble 
interactions; the interactions present were between residues: 11) V2396.51 with 
Y1975.58; 12) A2436.55 and L2446.56 with M1935.54; 13) L2476.59 with P1895.50 
(see Figure 5.1e). In the TM5-TM7 ensemble the interacting residues were: 14) 
N2847.49 with Y1975.58 and R1995.60; 15) Y2887.53 with R1995.60 (see Figure 5.1f). 
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In all six of the TM5 pairwise ensemble sets, the detected interactions took place 
at the same position within the TM5 helix indicating that a defined orientation is 
needed to establish a specific interaction in TM5 with other TM helices. The 
most prominently interacting residues in TM5 are: M1935.54, V1965.57, Y1975.58, 
R1995.60, and I2005.61. The identification of the presence of M1935.54 in the 
contact interface suggested that this residue may play a significant role in how 
the TM5 helix interacts with the other transmembrane helices. 
 
The occurrence of Cα-H......O contacts as a function of the interhelical 
axial distance in the database are between 6 and 12Å with an average of 
8.9Å[175] was then investigated. The shortest distance between interactions were 
found between TM5-TM1 and TM5-TM3 ensembles, which was about ~8Å. 
TM5-TM4 and TM5-TM6 distances were in the range of 8.5 to 9Å. The TM5-
TM2 ensemble showed that the interactions were at long distances, more than 
10Å, suggesting that these two helices do not favour heterodimerisation. In the 
TM5-TM7 ensemble, the interactions were also very long and were about ≥ 10Å. 
Not all the result observed were consisted with the experimental FRET and CD 
results on the A2A receptor[147], where they have only identified one 
heterodimer that was between the TM5-TM6 helices but in our method we have 
identified the same pair along with more interacting pairs, namely the TM5-
TM1, TM5-TM3 and TM5-TM4. 
 
5.3 Interacting interfaces of the TM1 pairwise ensembles 
Six simulation sets were tested. Following the application of the 10Å cut-
off, which included: 1) TM1-TM1; 2) TM1-TM2; 3) TM1-TM3; 4) TM1-TM4; 
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5) TM1-TM6 and 6) TM1-TM7. No stable dimers were detected in the TM1-
TM1 ensemble. 10% of TM1-TM2 and TM1-TM6 ensembles formed stable 
dimers in both simulations. In the TM1-TM3 and TM1-TM7 simulations, both 
sets were found to interact in 12% of ensembles. In the last set, the TM4-TM1 
simulation 14% of ensemble formed stable dimers. 
 
As explained previously, all the simulations in which dimerisation was 
identified had their trajectories combined and the results with heat maps of 
interactions observed at 12Å and 15Å compared (see Figure 5.2). The location of 
TM1 contact interface with the other helices was then mapped by comparison 
with the crystal structure of A2AR (3EML) on which the helices were modelled 
on to. 
 
5.3.1 Identification of the contact interfaces of the TM1 pairwise ensembles 
After identifying the interacting replicas in all sets, their trajectories were 
combined and the contact interface residues were identified by measuring the 
average interhelical contact distance between the two helices as explained 
previously in section 3.7.2 and results plotted at the two different distances, 12Å 
and 15Å as heat maps of interactions. 
 
In TM1-TM1 ensemble, it can be seen that TM1-TM1 does not come 
close enough to form potential specific interactions and none were detected in 
the combined trajectories, no results were obtained at the 12Å and also at the 
15Å cutoff (see Figure 5.2a). The interactions occurring within the averaged 12Å 
cutoff with an interhelical distances of about ~8Å in TM1-TM2 simulations were 
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between the residues: 1) F442.42, V462.44 and S472.45 with G231.49; 2) S472.45 with 
L191.45 and A201.46; 3) A502.48 with L191.45; 4) A512.49 with A171.43; 5) A542.52 
with A171.43; 6) A542.52, V552.53 and G562.54 with E131.39 (see Figure 5.2b). In 
TM1-TM3, interactions were found at a distance of ≥ 10Å between the following 
residues: 7) F793.28 and C823.31 with E131.39; 8) F833.32 with I161.51; 9) S903.39 
with N241.50 and the last interactions were 10) F933.32 and S943.33 with N241.50 
(see Figure 5.2c). From TM1-TM4 ensemble, the interaction interface at about 
8.5 to 9Å was between the residues: 11) W1294.50 with N241.50; 12) F1334.54 with 
A171.43 and A201.46; 13) G1364.57 and L1374.58 with I161.51 (see Figure 5.2d). In 
the TM1-TM6 ensemble the interacting interface in the simulations is at about ~ 
8Å, the interacting residues are: 14) F2426.43 with L191.45, A201.46 and I211.47; 15) 
W2466.47 with L141.49 and I161.51 (Figure 5.2,e). In TM1-TM7 simulations, the 
interactions interface present is between the residues: 16) M2707.35and Y2717.36 
with T111.36; 17) H2787.43 with V181.44; 18) S2817.46 with L221.48 (see Figure 
5.2f). 
 
The TM1-TM7 ensemble had the longest distance between the 
interactions ≥ 10Å. In the TM1-TM3 and TM1-TM4 ensembles, the distances 
between the two helices were in the range of 8.5 to 9Å. The lowest distance 
between the interacting residues was found between residues in the TM1-TM2 
and the TM1-TM6 ensembles at about ~8Å. In most of the six TM1 pairwise 
ensemble sets, the detected interactions took place at the same position within the 
TM1 helix indicating that a defined orientation is needed to establish a specific 
interaction in TM1 with other TM helices. The most prominently interacting 
residues in TM1 are: E131.39, I161.51, A171.43, A201.46, and N241.50 they are found 
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at the upper third of TM1 helix at the N-terminal side. The identification of the 
presence of E131.39 in the contact interface suggested that this residue may play a 
significant role in how the TM1 helix interacts with the other transmembrane 
helices as well as a contact point between two A2A receptors, as it is found at the 
exterior side of TM1 helix of the receptor. To investigate this possibility, we 
introduced one ensemble set that included a mutated TM1 helix (see Table 2.2) 
with a point mutation at the E131.39 where the substitution of glutamic acid to 
alanine was established. 
 
5.3.2 Identification of the mutated contact interfaces of the TM1-TM2 
ensemble 
Following the application of the 10Å screening cut-off, 8% of the TM1-
E131.39A-TM2 ensemble formed stable dimers. All the replicas, of those pairwise 
combinations in which dimerisation was identified after the 10Å cut-off had their 
trajectories combined and the results with heat maps of interactions observed at 
12Å and 15Å compared (see Figure 5.3). 
 
In the TM1-E13A1.39-TM2 mutation the contact interface between the 
helices was completely changed and most of the key interacting residues were 
lost and a new contact interface at a longer distances > 10Å at a new location 
was identified. The key interacting residues of the new contact interface are: 1) 
D522.50 with T111.37 and 2) D522.50 with A151.41. Mutation of the E131.39 in TM1 
causes major change in the way in which the two helices come together that may 
lead to a distribution of formation of A2A receptors homodimers. 
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Figure 5.2 Contact matrices showing specific pairwise interactions between TM1 and an 
A2A helix  
Contact matrices (heat maps) between two A2A helices showing specific interactions between 
TM1 (Helix 1) and TM1 (Helix 2) (a), between TM2 (Helix 1) and TM1 (Helix 2) (b), between 
TM3 (Helix 1) and TM1 (Helix 2) (c), between TM4 (Helix 1) and TM1 (Helix 2) (d), between 
TM6 (Helix 1) and TM1 (Helix 2) (e) and between TM7 (Helix 1) and TM1 (Helix 2) (f). The 
colour scale is as indicated in Figure 3.4. Circles indicate areas with key interhelical contacts.  
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Figure 5.3 Contact matrices showing specific pairwise interactions between mutated TM1-
E131.39 and TM2  
Contact matrices (heat maps) between two A2A helices showing specific interactions between 
TM2 (Helix 1) and TM1 (Helix 2). The colour scale is as indicated in Figure 3.4. Circles indicate 
areas with key interhelical contacts. Circles indicate areas with key interhelical contacts. The 
identified amino acid interactions are numbered as follows: 1) D522.50 with T111.37 and 2) D522.50 
with A151.41. 
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5.4 Interacting interfaces of the TM2 pairwise ensembles 
Five simulation sets were tested, which included: 1) TM2-TM2; 2) TM2-
TM3; 3) TM2-TM4; 4) TM2-TM6 and 5) TM2-TM7. At the 10Å screening 
cutoff, 24% of the TM2-TM2 ensemble resulted in the formation of stable dimers 
but there were no specific interactions identified between residues as explained 
previously in section 3.7.2 (see Figure 3.4d-f). In TM2-TM3 and TM2-TM7 
simulations, no stable dimers were seen between the two helices in both 
ensembles and no specific interactions were identified (see Figure 5.4a and d). In 
the TM2-TM4 ensemble, stable dimers were found to form in 8% of simulations 
(see Figure 5.4b) and 10% of the TM2-TM6 ensemble was observed to interact 
and form stable dimers (see Figure 5.4c). 
 
As explained previously, all replicas in which dimerisation was identified 
had their trajectories combined and the results with heat maps of interactions 
observed at 12Å and 15Å compared (see Figure 5.4). The location of TM2 
contact interface with the other helices was then mapped by comparison with the 
crystal structure of A2AR (3EML) on which the helices were modelled on to, it 
was located at the upper third of TM2 at the N-terminal side. The most 
prominent helix-helix interactions within the 12Å cutoff with an interhelical 
distance of more than ≥ 10Å in both ensembles where stable dimers were seen. 
In the TM2-TM4 simulations, the identified helical interface was between the 
residues: 1) P1394.60 and M1404.61 with F622.60 (see Figure 5.4b). In TM6-TM2 
simulations, the interaction interface was found between 2) H2506.52 with 
V552.53, G562.54, V572.55 and F622.60 (see Figure 5.4c). In these two simulations, 
the interactions between the two helices were far apart that is further than the 
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suggested length of the Cα-H......O bonds. 
 
 
Figure 5.4 Contact matrices showing specific pairwise interactions between TM2 and an 
A2A helix  
Contact matrices (heat maps) between two A2A helices showing specific interactions between 
TM3 (Helix 1) and TM2 (Helix 2) (a), between TM4 (Helix 1) and TM2 (Helix 2) (b), between 
TM6 (Helix 1) and TM2 (Helix 2) (c) and between TM7 (Helix 1) and TM2 (Helix 2) (d). The 
colour scale is as indicated in Figure 3.4. Circles indicate areas with key interhelical contacts.  
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5.5 Interacting interfaces of the TM3 pairwise ensembles 
The remaining four possible pairwise simulation sets were tested that 
included: 1) TM3-TM3; 2) TM3-TM4; 3) TM3-TM6 and 4) TM3-TM7. 
Following the application of the 10Å cut-off, 14% of the TM3 homodimer 
ensemble was identified to form stable dimers. In the TM3-TM4 ensemble, 12% 
of simulations where found to interact and form stable dimers. Simulations of 
TM3-TM6, stable dimers were found in 2% of simulations only. In the TM7-
TM3 simulations, no interaction and no stable dimers were seen between the 
helices in all of the replicas. 
 
5.5.1 Identification of the contact interfaces of the TM3 pairwise ensembles 
After identifying the interacting replicas in all sets, their trajectories were 
combined and the contact interface residues were identified by measuring the 
average interhelical contact distance between the two helices as explained 
previously in section 3.7.2 and results plotted at the two different distances, 12Å 
and 15Å as heat maps of interactions. 
 
The interactions occurring within the averaged 12Å cutoff with an 
interhelical of about ~8-10Å in the TM3-TM3 ensemble were between the 
residues found in the V863.35xxxSxxFS943.43 motif in the two helices, (see Figure 
5.5a). In the TM3-TM4 simulations was found between: 4) F1334.54 with V863.35 
and 5) W1294.50 with S903.39 and F933.42 (see Figure 5.5b). In the TM3-TM6 set, 
the interactions were found between: 6) H2506.52 with F833.32; 7) W2466.48 and 
H2506.52 with L873.36; 8) F2426.44 with S903.39 and the last one is between 9) 
V2396.41 with S943.43 (see Figure 5.5c). All the TM3 pairwise combination 
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simulations, except with the TM7 set where no stable dimers were identified, 
showed an interhelical distance between the two helices at the range of 8.5 to 9Å. 
In most of the TM3 pairwise ensemble sets, the interactions took place at the 
same position within the TM3 helix indicating that a defined orientation is 
needed to establish a specific interaction in TM3 with other TM helices. The 
most prominently interacting residues in TM3 are: V863.35, S903.39, F833.32, 
F933.42 and S943.43 they are found at the middle third of TM3 helix. 
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Figure 5.5 Contact matrices showing specific pairwise interactions between TM3 and an 
A2A helix  
Contact matrices (heat maps) between two A2A helices showing specific interactions between 
TM3 (Helix 1) and TM3 (Helix 2) (a), between TM3 (Helix 1) and TM4 (Helix 2) (b), between 
TM3 (Helix 1) and TM6 (Helix 2) (c) and between TM3 (Helix 1) and TM7 (Helix 2) (d). The 
colour scale is as indicated in Figure 3.4. Circles indicate areas with key interhelical contacts.  
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5.6 Interacting interfaces of the TM4 pairwise ensembles 
The remaining three possible pairwise simulation sets were tested that 
included: 1) TM4-TM4; 2) TM4-TM6 and 3) TM4-TM7. Following the 
application of the 10Å cut-off to the pairwise combinations of A2AR TM4 
pairwise ensembles revealed that in the TM4-TM4 and TM4-TM7 ensembles, 
6% of simulations were identified to have interacting helices and forming stable 
dimers. In the TM4-TM6 simulations, 14% of the 50 simulations where found to 
interact and form the stable dimers. 
 
5.6.1 Identification of the contact interfaces of the TM4 pairwise ensembles 
After identifying the interacting replicas in all sets, they had their 
trajectories combined and the contact interface residues were identified by 
measuring the average interhelical contact distance between the two helices as 
explained previously in section 3.7.2 and results plotted at the two different 
distances, 12Å and 15Å as heat maps of interactions. 
 
The interaction interface between the two helices in the averaged 12Å 
cutoff with interhelical distances of about ~8Å in the TM4-TM4 homodimer 
ensemble were between the residues found in the I1254.36xxCWxxS1324.53 motif 
on one helix with the residues found in the W1294.50xxxxA1344.55 motif on the 
other (see Figure 5.6a). The TM4-TM6 and TM4-TM7 pairwise combination 
simulations, both sets showed an interhelical distance of ≥ 10Å between the two 
helices. In the TM4-TM6, the interaction with the shortest distance was found 
between: 5) L2476.49 with F1334.54 (see Figure 5.6b). In the TM4-TM7 
simulations, the interactions were found between: 6) residues found in the 
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N2807.45SxVN2847.49 motif in TM7 with W1294.50 on TM4 and 7) the residues in 
the S2777.42HTNS2817.46 motif of TM7 with S1324.53 on TM4 (see Figure 5.6c).  
 
In the TM4 pairwise ensemble sets, the interactions took place at the 
same position within the TM4 helix indicating that a defined orientation is 
needed to establish a specific interaction in TM4 with other TM helices. The 
most prominently interacting residues in TM4 are: W1294.50, S1324.53 and 
F1334.54 that are found at the lower third of TM4 helix from the N-terminal side. 
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Figure 5.6 Contact matrices showing specific pairwise interactions between TM4 and an 
A2A helix  
Contact matrices (heat maps) between two A2A helices showing specific interactions between 
TM4 (Helix 1) and TM4 (Helix 2) (a), between TM4 (Helix 1) and TM6 (Helix 2) (b) and 
between TM4 (Helix 1) and TM7 (Helix 2) (c). The colour scale is as indicated in Figure 3.4. 
Circles indicate areas with key interhelical contacts.  
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5.7 Interacting interfaces of the TM6 pairwise ensembles 
The remaining two possible pairwise simulation for sets of TM6 were 
tested they included: 1) TM6-TM6 homodimer and 3) TM6-TM7 heterodimer. 
Following the application of the 10Å cut-off, in the TM6-TM6 ensemble, stable 
dimers were observed in only 4% of simulations. In the TM6-TM7 simulations, 
12% of simulations were identified as interacting helices and forming stable 
dimers. 
 
After identifying the interacting replicas in all sets, they had their 
trajectories combined and the contact interface residues were identified by 
measuring the average interhelical contact distance between the two helices as 
explained previously in section 3.7.2 and results plotted at the two different 
distances, 12Å and 15Å as heat maps of interactions. The interaction interface 
between the two helices in both ensemble sets at the 12Å cutoff was about ~10Å 
for both the TM6-TM6 and TM6-TM7 helix-helix interacting simulations. The 
most dominant interactions present between TM6-TM6 helices were between 
residues: 1) F2426.44 with F2426.44; 2) A2436.45 and W2466.48 on the other and 3) 
W2466.48 with C2456.47, W2466.48 and L2496.51 (see Figure 5.7a). In the TM6-
TM7, the prominent interaction was found between: 4) F2426.44 with S2777.42 and 
S2817.46 and 5) W2466.48 and S2777.42 (see Figure 5.7b). 
 
In the TM6 pairwise ensemble sets, the interactions took place at the 
same position within the TM6 helix indicating that a defined orientation is 
needed to establish a specific interaction in TM6 with other TM helices. The 
most prominently interacting residues in TM6 are: F2426.44, W2466.48 and 
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H2506.52 that are found at the middle of TM6 helix. 
 
5.8 Interacting interfaces of the TM7 pairwise ensembles 
The remaining homodimer pairwise ensemble set of the TM7-TM7 was 
tested. Following the application of the 10Å cut-off to the ensemble, stable 
dimers were detected in only 10% of simulations. 
 
After identifying the interacting replicas in the set, their trajectories were 
combined and the contact interface residues were identified by measuring the 
average interhelical contact distance between the two helices as explained 
previously in section 3.7.2 and the result plotted at the two different distances, 
12Å and 15Å as heat maps of interactions. The interaction interface between the 
two helices in the ensemble set at the 12Å cutoff exhibited weak interactions 
with interhelical distances of about ≥ 10Å between the two helices. From that, 
the most dominant interaction between the two helices was present between the 
S2777.42 residue on one helix with the H2787.43 residue on the other helix (Figure 
5.8). 
 
In all the TM7 pairwise ensemble sets, the interactions took place at the 
same position within the TM6 helix indicating that a defined orientation is 
needed to establish a specific interaction in TM6 with other TM helices. The 
most prominently interacting residues in TM6 are: S2777.42, H2787.43, N2807.45 
and S2817.46 that are found at the middle of TM7 helix.  
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Figure 5.7 Contact matrices showing specific pairwise interactions between TM6 and an 
A2A helix  
Contact matrices (heat maps) between two A2A helices showing specific interactions between 
TM6 (Helix 1) and TM6 (Helix 2) (a) and between TM6 (Helix 1) and TM7 (Helix 2). The 
colour scale is as indicated in Figure 3.4. Circles indicate areas with key interhelical contacts. 
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Figure 5.8 Contact matrices showing specific pairwise homodimer interactions between two 
TM7 helices  
Contact matrices (heat maps) between two A2A helices showing specific interactions between 
TM7 (Helix 1) and TM7 (Helix 2). The colour scale is as indicated in Figure 3.4. Circles indicate 
areas with key interhelical contacts.  
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5.9 Summary 
The aim of this chapter was to perform a comprehensive analysis in silico 
of every possible pairwise interaction between the seven different TM helices of 
the human A2A receptor. In all the A2A TM pairwise ensembles, the helices 
appeared to diffuse randomly within the lipid bilayer in the simulations sets and 
their positions along the bilayer were observed to be normal for both helices in 
the pair. 
 
The analysis of the ensemble sets demonstrates that there are 23 out of 28 
possible pairs of helices that formed dimers with varying interhelical distances. 
Not all the pairs of the ensemble sets showed a favor to form homo- or hetero- 
dimers. Stable contacts with an interhelical distance of ~8Å occurred in five 
pairs, namely: TM1-TM2, TM5-TM1, TM1-TM6 and TM4-TM4. Eight pairs 
establish a distance in the range of ~8.5 to 9Å, namely: TM1-TM3, TM1-TM4, 
TM3-TM3, TM3-TM4, TM3-TM6, TM5-TM3, TM5-TM4, and TM6-TM5. 
Seven pairs showed interhelical distance of ≥ 10Å, namely: TM1-TM7, TM2-
TM4, TM2-TM6, TM4-TM6, TM4-TM7, TM5-TM7 and TM7-TM7. One pair, 
the TM5-TM2, displayed an interhelical distance of mare than 10Å. The rest of 
the pairs exhibited no interactions between them, Table 5.1. These interhelical 
distances occur within the range that was found in between the bacteriorhodopsin 
helices, the 7.8-10.6Å interhelical distances range[175] it seems that these 
interactions are formed Cα-H......O bonds as they are above the approximate limit 
for backbone-to-backbone Cα-H......O bonds formation which is 7.6Å. The 
occurrence of Cα-H......O contacts between backbone-to-side-chain as a function 
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of the interhelical axial distance are between 6 and 12Å with an average of 
8.9Å[175]. 
 
Two of the transmembrane domains (TM1 and TM5) displayed the 
highest affinity to form dimers while TM2 exhibited the lowest tendency to form 
dimers, which may be due to its high hydrophobicity. Notably, a greater number 
of interacting pairs have been identified than were identified by through FRET 
and CD spectroscopy[147]. This may be due to the slight difference in TM 
sequences used in their study and the sequences used here or it may be due to the 
fact that they have stated that in SDS micelles only the strongest helix-helix 
interactions can be detected through FRET. 
 
Helices TM1 TM2 TM3 TM4 TM5 TM6 TM7 
TM1 None 
~ 8 Å 
Interaction 
8.5 to 9Å 
Interaction 
8.5 to 9 Å 
Interaction 
~ 8Å 
Interaction 
~ 8Å 
Interaction 
≥ 10Å 
Interaction 
TM2  None None 
≥ 10Å 
Interaction 
> 10Å 
Interaction 
≥ 10Å 
Interaction 
None 
TM3   
8.5 to 9Å 
Interaction 
8.5 to 9Å 
Interaction 
8.5 to 9Å 
Interaction 
8.5 to 9Å 
Interaction 
None 
TM4    
~8Å 
Interaction 
8.5 to 9Å 
Interaction 
≥ 10Å 
Interaction 
≥ 10Å 
Interaction 
TM5     
~ 8 Å 
Interaction 
8.5 to 9Å 
Interaction 
≥ 10Å 
Interaction 
TM6      
~10Å 
Interaction 
~10Å 
Interaction 
TM7       
≥ 10Å 
Interaction 
 
Table 5.1 Summary of the TM helix-helix interactions for the 28 studied 
helix pairwise combinations in silico. 
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The interacting interfacial residues between the helices is usually found 
in pairs of small residues spaced at i, i + 4 which are present on all helices, it is 
these small residues that have an increased occurrence in transmembrane helices 
and are usually involved in the interhelical Cα-H......O bonds formation[175]. The 
interactions interface we found between the transmembranes with the highest 
affinity to form dimers, at the ~8Å interhelical distance, is between the following 
motifs: 1) In TM1-TM2 dimer: E131.39xxIAxLAxxG231.49 motif that is mapped 
on the exterior on the TM1 helix with F442.42xVSxxAAxxAVG562.54 motif that 
is mapped to the exterior of the TM2 helix; 2) In TM5-TM1 dimer: 
A201.46xxAIxxNxxxC311.54 motif that is mapped on the interior of TM1 with 
P1895.50xxxMxxVYx R1995.60 motif that is mapped on the interior of TM5; 3) 
TM1-TM6 dimer: L141.49xIxxLAI211.47 motif that is mapped on the interior of 
TM1 with F2426.43xxx W2466.47 motif that is mapped on the interior of TM6 and 
4) TM4-TM4 dimer the interactions were found within the 
I1254.36xxCWxxS1324.53 motif that is mapped on the interior of one helix with 
the residues W1294.50xxxxA1344.55 found on the exterior of the other helix.  
 
The Cα-H......O bonds formed between the dimers are more likely to be in 
the form of backbone-to-side-chain rather than backbone-to-backbone as the 
interhelical distance between the two helices is above the limit of the backbone-
to-backbone interactions another reason is that the interacting interfacial residues 
in dimers do not consists of glycine, serine or threonine which is another feature 
observed in the backbone-to-backbone interaction Cα-H......O=C[175]. The 
mapping of the interaction motifs reveals that some of these residues were on the 
inner side of the helix and would only come in contact with each other if the 
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receptor would open-up like in the suggest second model of dimerisation where 
the hinge loop of the dimer opens, causing the helical domains to exchange and 
produce a domain-swapped dimer. 
 
Furthermore, from the simulations the involvement of serine and 
threonine residues in the interaction interface in a number of dimers formed, for 
example in the TM1-TM7 and in the TM4-TM7 dimers were observed at a 
longer interhelical distance ≥ 10Å, this is consistent with the other findings of 
that serine and threonine residues are the frequently found residues in the 
interhelical Cα-H......Oγ bonds, it has been establish that they each constitute 5% of 
the amino acid composition of transmembrane helices because of the donor 
potential of their polar side chains that can be satisfied by forming O-H......O 
hydrogen bonds to the carbonyl at i - 4 or i - 3 on the same helix[175, 182]. 
 
Additionally, a number of interactions between the formed stable dimers in 
the simulations involved the β-branched amino acids (either isoleucine, valine 
and leucine) on one helix with a small residue (either glycine, alanine and serine) 
on the other, this is coherent with the established finding of Senes et al, they 
have validated that the β-branched amino acids (isoleucine and valine) at the i, i 
+ 4 position, and to a less extent leucine, form pairs with the small residues 
(glycine, alanine and serine) at the position i, i + 1 and i, i + 2[182]. 
 
The eCG-MD results from the mutated TM1-E131.39A-TM2 ensemble set 
may provide a molecular explanation for the cause that alters the monomer:dimer 
ratio at a level of detail that could not be determined biophysically and would 
require structural biology studies to confirm experimentally. 
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Chapter 6 
Conclusion and Future Work 
 
 
6.1 Conclusions 
In this project, a method of ensemble-based coarse-grained classical 
molecular dynamics (eCG-MD) that would be used to predict protein-protein 
interactions between TM helices of dimeric GPCRs was developed and assessed. 
The method was applied and tested in two parts:  
 
1) Four different cases of homodimeric GPCRs, namely the A2A receptor, 
rhodopsin, CXCR4 and β1AR receptors for which experimental data exist were 
used to enable a comparison of the eCG-MD results with published experimental 
data. In each of these cases, the ensemble-based CG-MD methodology provides 
a reproducible measurement of the distance between interacting helices that 
corresponds well with the experimental data and is within the range of distances 
at which protein-protein interactions occur was identified.  
 
2) A comprehensive study of the seven TM of the A2AR helices was 
conducted. There were 21 possible heterologous pairs, seven possible homo-
interactions. All possible combinations helix-helix interactions were examined in 
the 26 different ensemble sets to identify novel interacting residues within the 
A2A receptor TM helices and a comparison was conducted to identify whether 
these results match the experimental data of the self-association of the helices of 
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the A2A adenosine receptor. The final mean distance between the two helices in 
every ensemble composed of 50 replicas in each set was used to identify the 
specific interactions between the helices in all of the ensemble sets. 
 
In the first part of the work presented in this thesis, the first case included 
the A2A adenosine receptor that had been experimentally shown to form 
homodimeric receptors through interactions between the TM5 helices of the two 
protomers. The results identified specific interactions involving the PxxxM motif 
of TM5 and, specifically, at the M1935.54 residue within that motif. The method 
accurately identified residues shown experimentally to be involved in TM5 
homodimerisation. In parallel with work done experimentally, the role of 
M1935.54 was investigated by two types of mutations the M193I5.54 and the 
M1935.54A. Characterizing the M193I5.54 mutation had no effect on the residues 
involved in contact interface, they were identical to those found in the wild-type 
but included I1935.54 in the interaction, despite the loss of the methionine at 
position 193. Characterizing the M1935.54A mutation, it was identified that the 
contact interface of the helices was completely changed and that the key 
interacting residues identified in the wild-type conformation had moved to a new 
position, preventing formation of TM5 homodimers. The results also provide a 
molecular explanation for the experimental finding that the M1935.54A mutation 
alters the monomer:dimer ratio at a level of detail that could not be determined 
biophysically and would require structural biology studies to confirm 
experimentally. The most prominently occurring interactions identified in the 
wild-type TM5-TM5 ensemble involved the Y1975.58 residue. The role of the 
Y1975.58 was investigated by mutating the Y1975.58 into alanine and 
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phenylalanine. Neither the Y1975.58A nor the Y1975.58F mutations had any effect 
on the way in which the two helices came together, suggesting that the Y1975.58 
may not be a key residue in the specificity of TM5-TM5 dimer formation but 
rather only a part of the interacting motif in the wild-type homodimer. 
 
The second case examined was that of the rhodopsin dimer, for which 
crystallographic data had identified contact interfaces between TM1 and TM2 
and between TM4 and TM5. Ensemble CG-MD confirmed dimerisation and the 
identification of specific interactions within each of these heterologous TM pairs. 
There is a striking convergence between the distances predicted computationally 
and those calculated from 1N3M, particularly for specific interactions between 
TMs 1 and 2, showing that the eCG-MD method is able to provide accurate and 
precise predictions in agreement with experimental findings. The method was 
also able to identify novel interfaces as seen in the third (CXCR4) and fourth 
(β1AR) cases studied, where a novel interface in CXCR4 between TM5 and TM5 
and a novel interface in β1AR between TM1 and TM1 were identified, in 
addition to confirming the previously identified contact interface between TM4 
and TM5 in the β1AR. The β1AR has been shown to form transient interactions 
whereas the β2 adrenergic receptor can form stable oligomers[181]. The ability to 
detect a stable dimer of TM1-TM1 in the β1AR shows the value of ensemble-
based simulations for the identification of transient interactions. 
 
In all of the cases studied, there appears to be a pattern emerging of the 
nature and location of the contact interfaces. It was observed as either a single 
interface, at TM5 in both the A2A and the CXCR4, or of two contact interfaces, 
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as seen in rhodopsin and the β1AR, one of which involves TM1 and the other 
between TM4 and TM5. Interestingly, interactions in TM5 are observed in all the 
of cases studied. As more dimeric GPCR crystal structures with corresponding 
biophysical and functional data become available, the conservation of this novel 
pattern will become clearer. 
 
In the second part of the thesis work, the comprehensive characterisation 
of the seven TM of the A2AR helices, eCG-MD of the pairwise ensemble sets 
revealed clearly that not all the pairs of the ensemble sets have a tendency to 
form homo- or heterodimers. There were 23 out of the 28 possible pairs of 
helices that formed dimers at varying interhelical distances and with different 
facing contact interfaces. The interactions with shortest distances appear to be 
between backbone-to-side-chain of the helices. Interestingly, the two helices 
displaying the highest affinity to form dimers were TM1 and TM5 of the A2A 
receptor, both identified in the emerging pattern of the nature and location of the 
contact interfaces in GPCRs mentioned previously, whilst TM2 exhibited the 
lowest affinity to form dimers. 
 
The method also showed that the different interfacial positioning of the 
interacting motifs can be recognized that can be either intradimeric contacts with 
exterior facing contact interfaces as seen between TM1-TM2 that can be found 
between two interacting receptors or interhelical interactions found internally 
within a receptor to stabilize the conformation of the structure such interactions 
interface were seen in the TM1-TM5 and TM1-TM6 dimers. Although the 
absence of the loops from the model system used in this method, it seems that it 
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is not detriment to the aim of study, as the ECL-1 in the A2A receptor between 
TM2 and TM3 is very short no interaction between the two helices was detected. 
In the case of TM5 and TM6, the ICL-3 is fairly long, interaction between these 
two helices was detected by the method as well as it was identified in the 
literature[147]. Thus it can be considered that the loops are not absolutely 
required for bringing the helices together nor are they required for holding them 
together (as suggested by other studies) although the fact that they may 
contribute to thermodynamic stability and are commonly required for the correct 
folding and function of integral membrane proteins and assist in the intradimeric 
contact is important to note[28]. 
 
The results from the eCG-MD method unequivocally demonstrate that 
sufficient conformational sampling is required in coarse-grained MD to obtain 
reproducible and reliable results. In the simulations preformed, several of the 
replicas within the ensemble failed to show any interactions and that a number of 
others began to interact late in the simulation at a point when accurate estimates 
of distance could no longer be achieved. A single trajectory simulation, 
particularly if either of these circumstances were to occur, would give inaccurate 
and potentially misleading results. Indeed, ensembles are required to obtain 
accurate and precise results. Error analysis was used to determine appropriate 
choices for ensemble size and run length. For ensemble size, it was observed that 
the rate of change in the standard deviation of the mean distance between helices 
decreased with increasing replica size and found that approximately 30 replicas 
was sufficient per ensemble to obtain reproducible results.  For run length, it was 
observed that the rate of increase in the standard deviation of the mean distance 
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between helices increased with increasing run length, but that the rate of increase 
slowed substantially after approximately 300 ns. Interestingly, the negative 
control, the TM2-TM2 ensemble, included in the eCG-MD simulations showed 
no variation in the standard deviation of the mean distance between helices as a 
function of run length and a low standard deviation with a very rapid decrease to 
a constant value at an ensemble size of ~15 replicas. This behavior was notably 
different from simulations in which interactions were identified and provides a 
means of confirming the absence of interaction 
 
In conclusion, a systematic, reproducible and reliable computational 
protocol for determining the specific points of interaction between GPCR dimers, 
eCG-MD, was developed and validated using experimental data. The method 
discriminates between residues in TM helices that form specific interactions and 
residues that are in close proximity but do not interact. The work here extends 
the recent findings of ensemble-based fully atomistic MD studies, which have 
shown that an ensemble-based approach is required to generate predictions of 
protein properties that correlate well with experimental data. 
 
Lastly, the use of eCG-MD simulations has provided a valuable tool to 
the time and length scales of systems used compared to what is possible with 
traditional all-atom models. This is easily explained by the required turnaround 
times of days, week, or up to months. Our tests showed that CG-simulations (one 
ensemble) run on 16 CPU cores on Legion for 500 ns completed within 
approximately 150 hours (an actual week). The same CG-simulations (one 
ensemble) run on 16 CPU cores on Grace for 500 ns completed within 
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approximately 72 hours (3 days). That is a much shorter run time than all-atom 
MD simulations, where it was reported that a 6 ns replica of an all-atom MD 
simulation was produced within 15 hours (using 64 CPU cores)[183] on a much 
smaller system. 
 
 
6.2 Future work 
The main objective behind the work of this thesis was to develop a method 
that can identify or predict the helix-helix interactions of GPCRs transmembrane 
domains. The method provided an ability to predict contact interfaces 
computationally and the error analysis enabled the identification of non-
interacting regions in the A2A receptor. This method can enhanced by providing 
and writing an automated pipeline software for performing high throughput eCG-
MD simulations of α-helical peptides in lipid bilayer membranes to facilitate the 
running and analysis  of such simulations ensembles. 
 
Running the A2A TM5, TM2 wild-types and mutated M1935.54 ensembles 
sets for a longer time from 500 ns to µs would constitute a logical follow-up on 
these experiments to see if longer times might change the results observed in the 
types and location of the interactions involved between the helices. 
 
Furthermore, running simulations with an intact A2A receptor could be 
implemented to help in further understanding of the types of interactions 
produced in the pairwise comprehensive analysis of TM helices simulations 
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performed. Ensembles performed with two or more intact A2A receptors 
preformed in silico would provide a means of confirming whether the proposed 
interfaces identified from interacting TM helices, as performed in this study, 
form part of the interface. The confirmation that computational simulations run 
with intact receptor proteins, rather than with isolated receptor TM domains, 
would enable the development of methodologies to rapidly identify interacting 
GPCR partners and contact interfaces at greatly reduced computational cost, 
compared with running much larger simulations with intact receptors and could 
potentially offer insight into the means by which GPCR protomers form 
homodimers. 
 
 As described in Chapter 3, the unsuccessful attempts to access the 
dimerisation interface experimentally and the effect of mutation on TM5 
M1935.54 by the BiFC fluorescent protein and the measurement of the cAMP 
levels due to problematic constructs and the difficulty in determining the cell 
number can be continued by first establishing a stably transfected cell line with 
the wild-type and mutated A2A receptor followed by the functional analysis. 
 
Additionally, it is of great interests to take forward the novel findings of 
the eCG-MD work and investigate experimentally the residue identified on the 
exterior side of TM1 part of the interacting interface between TM1 and TM2, 
This residue, E131.39, when mutated computationally, abolished the contact 
interface between TM1 and TM2, which is the proposed interface between two 
A2A protomers. A number of different means of characterizing the effects of 
E131.39 could be employed, including peptide studies, co-immunoprecipitation, 
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FRET and other functional experiments. 
 
In summary, the eCG-MD methodology developed here is of great utility 
in further understanding GPCR function and also has broad applicability to many 
different types of membrane proteins, including receptor tyrosine kinases, ion 
channels, transporters and oligomeric complexes of various combinations of 
these. 
 
In addition, in chapter 5, the comprehensive simulations between the 
seven different TM helices of the human A2A receptor produced several pairwise 
interactions. Identification if any of these amino acid residues are part of 
conserved motif is an important next step and also to distinguish whether they 
are part of sequence or structural motifs. This could be verified by one of the 
covariation analysis methods[184] that can detect conserved residues involved in 
dimer interfaces; including: mutual information or statistical coupling analysis. 
This can be followed by multiple sequence alignment to verify if the identified 
amino acid were conserved. Some of the bioinformatical tools used in multiple 
sequence alignment include: Clustal Omega; Kalign; MUSCLE; and T-Coffee 
among others. 
 
Finally, there are a number of different approaches available that aim to 
identify or predict the protein-protein interaction interfaces. In this thesis, we 
have developed an ensemble-based coarse-grained molecular dynamics method 
that was used to predict the protein-protein interactions between TM helices of 
dimeric GPCRs. It was used to investigate the helix-helix dimerisation interface 
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of four types of interacting GPCRs. One of the investigated GPCRs, A2A, has no 
dimeric structure available in the PDB until now. So the results obtained through 
this method for the A2A receptor were assessed by comparing its results to the 
results obtained from the other three types of GPCRs that had dimeric structures 
in the PDB. From the method, the measurement of the distance between 
interacting helices corresponded well with the experimental data and is within 
the range of distances at which protein-protein interactions occur. As more 
dimeric GPCR crystal structures become available, their interacting interfaces 
can be assed by the eCG-MD method and then compare the results with the 
results obtained from the CAPRI method. CAPRI is a blind protein-protein 
prediction method, which uses the 3D structure of a protein or atomistic 
coordinates to predict the form or ability of two proteins to associate using 
docking algorithms. CAPRI prediction methods are a useful complement to 
experimental data. It uses X-ray or NMR protein structure of protein-protein 
complexes[185].  
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